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CHAPTER Ι 
INTRODUCTION 

INTRODUCTION 
Calcium antagonists are a heterogeneous class of recently developed arterio-
lar vasodilators, which lower blood pressure by causing a decrease in peri-
pheral vascular resistance (1,2). They act through interference with the cal-
cium metabolism of the vascular smooth muscle cells, especially in the arte-
rioles, and may therefore be considered as direct vasodilatory drugs. 
This thesis is concerned with the effects of two dihydropyndine calcium an-
tagonists - nifedipine and felodipine - on blood pressure in hypertensive and 
normotensive subjects. Special attention is paid to three compensatory mecha-
nisms that counterbalance the blood pressure lowering effect of vasodilation 
(3): sodiLTi and fluid retention by the kidney, activation of the sympathetic 
nervous system, and activation of the renm-angiotensin-aldosterone system. 
In this introduction we will discuss in three short sections the role of ar-
teriolar vasodilators in the medical treatment of hypertension, the mecha-
nisms by which calcium antagonists are thought to interfere with vascular 
smooth muscle cell contraction, and finally, our previous clinical experience 
with nifedipine, which formed the starting point of the present studies. 
Vasodilator drugs in the treatment of hypertension 
Arterial hypertension is one of the most frequent physiological disturbances 
in Western society. When untreated, it may lead to significant morbidity and 
mortality due to cardiac hypertrophy and failure, renal damage, cerebral com-
plications, and severe arteriosclerosis. There is much evidence that an ab-
normally high peripheral vascular resistance is the most prominent haemodyna-
mic disturbance in patients with established hypertension (4). Medical thera-
py should preferably be directed at the reversal of the supposed pathophysio-
logical derangements (3), and, above all, be free of unwanted side effects 
that will interfere with patient compliance. At first sight, directly acting 
vasodilator drugs such as hydralazine, diazoxide, and minoxidil appear to be 
ideally suited for this purpose. Unfortunately, the compensatory mechanisms 
depicted in Figure 1 attenuate the blood pressure lowering effect of these 
drugs, and lead to disturbing side effects (3,5,6). 
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Figure 1. Compensatory reactions to arteriolar vasodilatation (reproduced by 
permission from ref. 45) 
Koch-Weser suggested that the fall in blood pressure secondary to vasodilator 
monotherapy is counteracted by an increase in cardiac output and by the re-
tention of sodium and water by the kidney (3). The increase in cardiac output 
is caused by a rise in ß1-adrenergic activity and by a decrease in vagal tone 
(7fB) as a consequence of the activation of the baroreceptors by the fall in 
blood pressure. Sympathetic overactivity may lead to complaints of palpita-
tions, but may also contribute to activation of the renin-angiotensin system, 
and to a noradrenaline-mediated α-adrenergic increase in peripheral resis­
tance. As shown in Figure 2, neuronally released noradrenaline can increase 
vascular smooth muscle tone by activation of two types of postsynaptic al­
pha-receptors: the al-receptors, which are selectively blocked by prazosin, 
and the a2-receptors, on which this drug has no effect. Antihypertensive the­
rapy with vasodilators causes a rise in plasma renin activity. The activation 
of renin leads to the formation of angiotensin I, a peptide prehormone which 
is rapidly converted to the active hormone angiotensin II. Angiotensin II is 
a very potent vasoconstrictor, but also has a sodium retaining effect on the 
kidney, both through a direct effect on proximal tubular sodiun reabsorption 
(9), and by stimulating adrenal aldosterone release. Aldosterone enhances the 
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Figure 2. The effects ot neuronally released noradrenaline (NA) and circula­
ting adrenaline (ADR) on postsynaptic P2, аг, and a1 receptors. +: 
stimulating, and - inhibiting effect. MLCK: myosin light chain ki­
nase, which stimulates contraction of the vascular smooth muscle 
cell (14). 
renal reabsorption of sodiim via the cortical collecting tubule (10). Intra-
renally released noradrenaline from the sympathetic nerve endings may also 
directly increase a-receptor mediated sodium reabsorption (11). The clinical 
consequences of these reactions are that the fall in peripheral resistance 
caused by hydralazine, diazoxide, and minoxidil monotherapy is counteracted, 
which results in a relatively minor decrease in blood pressure, and that the 
patient may complain of palpitations and oedema (3) . Especially in hyperten­
sive patients with renal failure, the potent vasodilators diazoxide or mino­
xidil are frequently needed. In these patients, an already impaired renal 
ability to excrete sodium may aggravate the sodium and fluid retention secon­
dary to vasodilation, necessitating high doses of potent diuretics (5). 
Koch-Weser (12) pointed out that a combination of a directly acting vasodila­
tor, a betablocker and a diuretic (triple therapy) would enhance the effecti­
veness of vasodilator therapy and diminish the compensatory reactions leading 
to palpitations and oedema. This approach has proved to be very successful in 
subsequent years (5,6), but the side effects of the strong vasodilators dia-
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zoxide and minoxidil and the lesser potency of hydralazine prompted the 
search for new drugs that directly or indirectly affect vascular smooth 
muscle tone. This led to the discovery of the calcium antagonists, vasodila­
tors that form the subject of the present thesis. 
The role of calcium in the contraction of the vascular smooth muscle cell and 
cellular mechanism of action of calcium antagonists 
In recent years, the body of knowledge of the role of intracellular free 
ionized calcium levels in the contractile mechanism of the vascular smooth 
muscle cell has grown substantially (13). An increase in cytosolic calcium 
concentration from 10"^M to 10~6 or Ю'^м causes a contraction (13) of the 
actin and myosin filaments of the vascular smooth muscle cell via a cascade 
of intracellular mechanisms, in which the calmodulin activated enzyme myosin 
light chain kinase (MLCK, Fig.3) plays a key role (14). When this contraction 
is generalized, it leads to an increase in vascular tone and peripheral re­
sistance (15). A decrease in cellular free calcium concentration, back to 
10"^M, after the extrusion of calcium from the cell or its sequestration into 
intracellular stores (sarcoplasmatic reticulum, inner surface of cell mem­
brane, mitochondria), leads to relaxation (Fig.3). 
An important source for the cytosolic ionized calcium (Ca^4-) is the extracel­
lular fluid, where calcium is present in the 10~^M range. Since the plasma 
membrane is relatively impermeable to calcium ions, the extracellular calcium 
needed for contraction has to enter the cell via so-called calcium channels 
which may be opened by depolansation (voltage operated channels, VOC, 16). 
In vitro, VOC appear to be involved in the vascular reaction to stretch 
(17). Hormones, such as angiotensin II and noradrenaline may increase calcium 
influx also via so-called receptor operated channels (ROC, 1Θ). The contrac­
tion seen in experimental preparations exposed to these hormones is greater 
than can be explained by transmembrane transport of calcium alone, suggesting 
that release of Ca2 + from intracellular stores, and in particular from the 
sarcoplasmatic reticulum, is also involved in this 'pharmacomechamcal coup­
ling' process (19). The release of sarcoplasmatic Са^* may be induced by a 
small amount of Ca2 + that has entered through the ROC and also by inosme 
triphosphate (IP3), generated from ROC activation-induced phosphatidylinosi­
tol break-down, acting as a 'second messenger' (20). In vitro experiments 
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Figure 3. The central role of cellular calcium metabolism in the contractile 
activity of vascular smooth muscle cells. An increase in cytosolic 
calcium leads to calcium-calmodulin (CLM) binding. The triggered 
complex (CLM*) activates the enzyme myosin light chain kinase 
(MLCK), which finally leads to contraction of the cell. Cytosolic 
calcium is normally kept at low levels by the activity of 
Ca-ATPase, which favours calcium extrusion from the cell, and cal­
cium uptake into the cellular organelles, in particular the sarco-
plasmatic reticulum (SR). Some calcium may also be extruded by the 
Na-Ca exchange system. Ionized free calcium levels in the cell may 
be increased by calcium entry into the cell through voltage operat­
ed channels (VOC), and through receptor operated channels (ROC). 
Hormone-receptor binding may increase calcium entry (path 1 and 2), 
but also leads to calcium release from the intracellular stores 
(path 3 and 4). Calcium release from the SR may be effected by pre­
viously released Ca (path 3) from membrane stores (calcium-induc-
ed-calcium release), or by inositol triphosphate (IP3), generated 
from ROC activation-induced phosphatidylinositol break-down (path 
4). 
with vascular smooth muscle in the absence of Ca2+ in the bathing solution 
show that repeated noradrenaline or angiotensin II induced contractions de­
crease in amplitude, suggesting that the entry of Ca2+ from the exterior is 
necessary for the maintenance of agonist induced contraction as well (21). 
Intracellular Сэ^+ levels may be lowered by re-uptake of calcium by the in-
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tracellular stores, but also by extrusion from the cell, an energy dependent 
mechanism against a steep concentration gradient. Much of the energy needed 
for Ca2+ extrusion is derived from ATP hydrolysis by the enzyme Ca-ATPase 
(Fig.3, ref.22). Some Ca2 + may also be extruded by an exchange against sodium 
ions, where the energy needed is derived from sodium entry following its 
electrochemical gradient from exterior to interior. Sodium balance over the 
membrane is re-established by the activity of the enzyme Na,K-ATPase, as pro­
posed by Blaustem (23). In the light of these considerations, showing the 
importance of intracellular Ca2+ levels for the contractile activity of vas­
cular smooth muscle, it is not surprising that experimental evidence was 
found indicating that many of the clinically useful vasodilators may inter­
fere with cellular calcium metabolism (24). 
Calcium antagonists are a heterogeneous group of vasodilatory compounds, 
which all have in common that the influx of extracellular Ca2+ into the vas­
cular smooth muscle cell following experimental stimuli is impaired (25). On 
the basis of clinical and experimental evidence the calcium antagonists may 
be subdivided into three main groups (16): the dihydropyndine group, the ve­
rapamil derivatives, together with diltiazem, and finally the diphenylalkyl-
amines which have less vasodilatory potency in vivo. Because verapamil and 
diltiazem show significant negative chronotropic and dromotropic activities 
on the heart in vivo (1,2), they may be less 'pure' vasodilators than the di­
hydropyndine derivatives (DHP). Therefore, we have chosen to use the DHP in 
the investigations discussed in this thesis, and in the following only DHP 
effects will be discussed. 
Since DHP all bind to the calcium channel in a stereospecific way, and this 
binding is inhibited by the addition of another analogue (26), they are con­
sidered as a rather homogeneous group of compounds. However, differences be­
tween individual DHP in effects on calcium entry do exist. For instance, the 
experimental DHP Bay К 8644 does not block, but rather enhances Ca2 + entry, 
and behaves as a competitive antagonist of the DHP prototype nifedipine in 
vitro as well as in vivo (27). The dihydropyndines that were used in our 
studies, nifedipine, felodipine, nitrendipine, nimodipine, nisoldipine and 
niludipine all block calcium entry. It is unclear at present whether slight 
differences in clinical effects of these DHP relate to other possible cellu­
lar mechanisms of actions than calcium entry. Felodipine, for instance, inhi-
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bits calcium binding to calmodulin in vitro (2Θ), but some metabolites that 
are devoid of vasodilatory activity do the same (29). Pan and Jams (30) 
found that nimodipine and nitrendipine stimulated the enzyme Na,K-ATPase in 
vitro, which, according to Blaustem's hypothesis of Na-Ca exchange, leads to 
more effective Ca + extrusion from the cell (23). Other cellular mechanisms 
have also been postulated (31). It is difficult to extrapolate these results, 
obtained with high concentrations (10- to 10-6M) of DHP in vitro, to the va­
sodilatory effects in vivo. DHP are effective vasodilators at plasma concen-
α g 
trations in the 10- to 10" M range, which is substantially lower (32). Like 
other calcium antagonists, DHP appear to block preferentially the VOC, al­
though there may be some interference with effects of ROC activation also 
(16). The inhibition of postsynaptic <i2-mediated vasoconstriction (Fig.2) in 
pithed rats (33) or the hindlimb of anaesthesized dogs (34) by DHP may be an 
example in this regard. 
Differences between individual DHP may exist with regard to the effects on 
cardiac and on vascular tissue in vitro (35). In antihypertensive treatment 
this is of doubtful relevance since in vivo compensatory mechanisms to vaso­
dilation (Fig.1) can effectively counteract direct negative cardiac effects 
of DHP (7). In high doses, in vitro, DHP may have negative effects on Ca 2 +-
dependent stimulation of hormone release from isolated endocrine tissue. 
Apart from a possible antagonism of angiotensin II induced aldosterone re­
lease from the adrenal by some, but not by all (36) DHP, fairly extensive 
clinical experience indicates that these effects are not seen with the lower 
doses of DHP, as used in clinical practice (37). 
Clinical effects of nifedipine in hypertensive patients and aims of the in­
vestigations. 
Our previous experience with the acute effects of nifedipine in hypertensive 
patients forms the basis of the studies presented in this thesis (38,39). 
Sublingual nifedipine safely lowered blood pressure in 51 hypertensive pa­
tients, and also in 10 patients with a hypertensive crisis. The fall in blood 
pressure appeared to be due to vasodilation, as was suggested by side effects 
such as facial flushing and headache. Furthermore, there was evidence of a 
reflex sympathetic stimulation: an increase in heart rate was noted and plas­
ma renin activity (PRA) rose. The increase in heart rate and the lack of ECG 
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changes in PQ and QRS intervals after the administration of nifedipine sug-
gest that the direct negative cardiac effects of nifedipine in vitro, are ef-
fectively counteracted in vivo (7). 
Of interest was the observation that plasma aldosterone levels did not rise, 
in spite of the rise in PRA. We found rises in haemoglobin, haematocnt, to-
tal protein, and albumin levels that were indicative for a relative decrease 
in plasma volume. In acute experiments, nifedipine has a diuretic and natriu-
retic effect in humans (40), which might well explain these findings. The 
response in patients with renal failure was similar to those with normal kid-
ney function. Although the effects of a single dose of nifedipine may last 
for several hours (38), nifedipine capsules had to be given at least four to 
six times daily to achieve a stable reduction of blood pressure in chronic 
antihypertensive treatment, because of the rapid metabolism and elimination 
of the drug (41). Furthermore, a substantia] proportion (25%) of the patients 
appeared to be resistant to the antihypertensive effect of nifedipine (38). 
Other authors have reported more favourable effects of nifedipine in chronic 
antihypertensive treatment (42,43). The recent availability of a nifedipine 
tablet formulation with improved pharmacokinetic properties (41) may, how-
ever, extend the clinical usefulness of nifedipine in the treatment of hyper-
tension. 
The short-lasting effects of the nifedipine capsules prompted us to evaluate 
the clinical effects of the related DHP felodipine, which has a longer plasma 
half-life (44) and appears to be more potent on a molar basis (35). In con-
trast with nifedipine, felodipine is not degraded chemically by exposure to 
daylight. This enabled us to use felodipine intravenously in the acute stu-
dies. The general goal of the present studies was to assess the antihyperten-
sive efficacy of felodipine in the management of acute hypertension and after 
long-term treatment, and to investigate the extent to which dihydropyndines 
elicit compensatory reactions of the body in response to their vasodilating 
effects, in hypertensive, and in normotensive subjects. 
10 
REFERENCES 
1. Opie, L.H. 1984. Calcium antagonists. Mechanisms, therapeutic indications 
and reservations: a review. Q.J.Med., New Series LIII: 1-16. 
2. Stone, P.H., E.A. Antman, J.E. Muller, and E. Braunwald. 1980. Calcium 
channel blocking agents in the treatment of cardiovascular disorders. 
Part 11: Hemodynamic effects and clinical applications. Ann.Intern.Med. 
93: 886-904. 
3. Koch-Weser, J. 1974. Vasodilator drugs in the treatment of hypertension. 
Arch.Intern.Med. 133: 1017-1027. 
4. Folkow, B. 1982. Physiological aspects of primary hypertension. Physiol. 
Rev. 62: 347-504. 
5. Thien, Th., F.Th.M. Huysmans, and R.A.P. Koene. 1980. Treatment of hyper-
tension with the vasodilator minoxidil. Prog.Pharmacol. 3/4: 125-129. 
6. Thien, Th., F.Th.M. Huysmans, E.L.M. Burm, and R.A.P. Koene. 1980. Con-
tribution of ß-adrenoceptor blockade to the antihypertensive effect of 
oral diazoxide. In: Treatment of hypertension with diazoxide. Th.Thien. 
Thesis, Nijmegen: 105-118. 
7. Millard, R.W., D.A. Lathrop, G. Grupp, M. Ashraf, I.L. Grupp, and A.W. 
Schwarz. 1982. Differential cardiovascular effects of calcium channel 
blocking agents: potential mechanisms. Am.J.Cardiol. 49: 499-506. 
8. Hallbäck-Nordlander, M.I.L., and P.G. Thalén. 1983. Differential reset-
ting of vagal and sympathetic component of baroreflex control in SHR-ef-
fects of antihypertensive therapy with felodipine. J.Hypertension 1 
(Suppl.2): 217-219. 
9. Harns, P.J., and L.G. Navar. 1985. Tubular transport responses to angio-
tensin. Am.J.Physiol. 248: F621-F630. 
10. Knöchel, J.P., and M.G. White. 1973. The role of aldosterone in renal 
physiology. Arch.Intern.Med. 131: 876-884. 
11. DiBona, G.F. 1985. Neural control of renal function: role of renal alpha 
adrenoceptors. J.Cardiovasc.Pharmacol. 7 (Suppl.8): S18-S23. 
12. Koch-Weser, J. 1973. Correlation of pathophysiology and pharmacotherapy 
in primary hypertension. Am.J.Cardiol. 32: 499-510. 
13. Rasmussen, H. 1983. Cellular calcium metabolism. Ann.Intern.Med. 98 (part 
2): 809-816. 
14. Movsesian, M.A. 1982. Calcium physiology in smooth muscle. Prog. Cardio-
vase.Dis. XXV: 211-224. 
15. Webb, R.C., and D.F. Bohr. 1981. Recent advances in the pathogenesis of 
hypertension: consideration of structural, functional, and metabolic vas-
cular abnormalities resulting in elevated arterial resistance. Am. Heart 
J. 102: 251-264. 
16. Spedding, M., and I. Caverò. 1984. "Calcium antagonists": a class of 
drugs with a bright future. Part II. Determination of basic pharmacologi-
cal properties. Life Sci. 35: 575-587. 
17. Fleckenstein, Α. 1983. Inhibition by calcium antagonists of stretch-in­
duced autoregulatory vasoconstriction. In: Calcium antagonism in heart 
and smooth muscle. Experimental facts and therapeutic prospects. A. 
Fleckenstein. John Wiley 4 Sons, New York. 261-267. 
18. Bolton. T.B. 1979. Mechanisms of action of transmitters and other sub­
stances on smooth muscle. Physiol.Rev. 59: 606-718. 
19. Casteels, R., and G. Droogmans. 1983. The role of calcium in contraction 
of vascular smooth muscle. In: Calciun channel blocking agents in the 
treatment of cardiovascular disorders. P.H. Stone and E.M. Antman. Eds. 
Futura, New York. 59-80. 
20. Berndge, M.J., and R.F. Irvine. 1984. Inositol triphosphate, a novel se­
cond messenger in cellular signal transduction. Nature 312: 315-321. 
11 
21. Deth, R.. and С van Breemen. 1977. Agonist induced release of intracel­
lular Ca2 + in the rabbit aorta. J.Membr.Biol. 30: 363-380. 
22. Hurwitz, L., D.F. Fitzpatnck, G. Debbas, and E.J. Landon. 1973. Locali­
zation of calciun pump activity in smooth muscle. Science 179: 384-386. 
23. Blaustein, M.P. 1977. Sodium ions, calcium ions, blood pressure regula­
tion, and hypertension: a reassessment and a hypothesis. Am.J.Physiol. 
232: C165-C173. 
24. Rahwan, R.G., M.F. Piascik, and D.T. Witiak. 1979. The role of calcium 
antagonism in the therapeutic action of drugs. Can.J.Physiol.Pharmacol. 
57: 443-460. 
25. Fleckenstein, A. 1983. History of calcium antagonists. Circ.Res. 52 
(Suppl.I): 3-16. 
26. Meyer, H., F. Bossert, E. Wehinger, R. Towart, and P. Bellemann. 1983. 
Chemistry of calcium antagonists. Hypertension 5 (Suppl.II): II2-II7. 
27. Schramm, M., G. Thomas, R. Towart, and G. Franckowiak. 1983. Activation 
of calcium channels by novel 1,4-dihydropyridines. A new mechanism for 
positive inotropics or smooth muscle stimulants. Arzneim.-Forsch./Drug 
Res. 33 (II): 1268-1272. 
28. Boström, S-L., B. Ljung, S. Mardh, S. Forsén, and E. Thulin. 1981. Inter-
action of the antihypertensive drug felodipine with calmodulin. Nature 
292: 777-778. 
29. Andersson, Α., T. Drakenberg, E. Thulin, S. Forsén. 1983. A H'Cd and "Ή 
NMR study of the interaction of calmodulin with D 600, trifluoperazine 
and eome other hydrophobic drugs. Eur.J.Biochem. 134: 459-465. 
30. Pan, M., and R.A. Janis. 1984. Stimulation of Na+,K+-ATPase of isolated 
smooth muscle membranes by the Ca^+ channel inhibitors, nimodipine and 
nitrendipine. Biochem.Pharmacol. 33: 787-791. 
31. Janis, R.A., and A. Scnabine. 1983. Sites of action of Ca^ -·- channel in­
hibitors. Biochem.Pharmacol. 32: 3499-3507. 
32. Silver, P.J., J.M. Ambrose, R.J. Michalak, and J. Dachiw. 1984. Effects 
of felodipine, nitrendipine and W-7 on arterial myosin phosphorylation, 
actin-myosin interactions and contraction. Eur.J.Pharmacol. 102: 417-424. 
33. Van Meel, J.С.Α., Α. de Jonge, H.O. Kalkman, В. Wilffert, Р.В.M.W.M. 
Timmermans, and P.A. van Zwieten. 1981. Organic and inorganic саісіші an­
tagonists reduce vasoconstriction in vivo mediated by postsynaptic 
alpha-2-adrenoceptors. Naunyn-Schmiedeberg's Arch.Pharmacol. 316: 288-
293. 
34. Saeed, M., J. Holtz, D. Eisner, and E. Bassenge. 1983. Attenuation of 
sympathetic vasoconstriction by nifedipine: the role of vascular alpha-
2-adrenoceptors. Eur.J.Pharmacol. 94: 149-153. 
35. Ljung, B. 1985. Vascular selectivity of felodipine. Drugs 29 (Suppl.2): 
46-58. 
36. Pasanisi, F., H.L. Elliott, and J.L. Reid. 1985. Vascular and aldosterone 
responses to angiotensin II in normal humana: effects of nicardipine. 
J.Cardiovasc.Pharmacol. 7: 1171-1175. 
37. Millar, J.A. and A.D. Struthers. 1984. Calcium antagonists and hormone 
release. CI in.Sci. 66: 249-255. 
38. Huysmans, F.Th.M., Th.A. Thien, H.E. Sluiter, and R.A.P. Koene. 1983. 
Acute treatment of hypertension with nifedipine. Neth.J.Med. 26: 256-261. 
39. Huysmans, F.Th.M., H.E. Sluiter, Th.A. Thien, and R.A.P. Koene. 1983. 
Acute treatment of hypertensive crisis with nifedipine. Br.J.CIin.Phar­
macol. 16: 725-727. 
40. Kliitsch, K., P. Smidt, and J. Grosswendt. 1972. Der Einfluss von BAY a 
1040 auf die Nierenfunktion des Hypertonikers. Arzneim. Forsch./Drug 
Res. 22: 377-380. 
12 
41. Kleinbioesem, C.H. 1985. Nifedipine: Clinical pharmacokinetics and haemo-
dynamic effects. Thesis, Leiden. 
42. Lederballe Pedersen, 0., and E. Mikkelsen. 1978. Acute and chronic ef­
fects of nifedipine in arterial hypertension. Eur.J.Clin.Pharmacol. 14: 
375-381. 
43. Aoki, K., K. Sato, Y. Kawaguchi, and M. Yamamoto. 1982. Acute and long-
term hypotensive effects and plasma concentrations of nifedipine in pa­
tients with essentia] hypertension. Eur.J.CIin.Pharmacol. 23: 197-201. 
44. Edgar, В., CG. Regardh, G. Johnsson, L. Johansson, P. Lundborg, I. Loef-
berg, and 0. Rönn. 1985. Felodipine kinetics in healthy men. Clin.Pharma-
col.Ther. 38: 205-211. 
45. Thien, Th. 1980. Vasodilation in the treatment of hypertension. In: 
treatment of hypertension with diazoxide. Thesis, Nijmegen. 9-26. 
13 

CHAPTER II 
THE INFLUENCE OF ALPHA-)-ADRENERGIC BLOCKADE ON THE ACUTE ANTIHYPERTENSIVE 
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The Influence of Alpha
r
Adrenergic Blockade on the Acute 
Antihypertensive Effect of Nifedipine 
H E Sluiter', F Th M Huysmans1, Th A Thien2, and R A Ρ Koene' 
'Department of Medicine Division of Nephrology and 'General Internal Medicine, Sint Radboud Ziekenhuis University of Nijmegen, 
The Netherlands 
Summary. The hypotensive effect of vasodilator 
monotherapy in hypertension is attenuated by a bar 
oreceptor-mediated increase in the sympathetic re­
lease of noradrenaline Nifedipine induces a nse in 
noradrenaline release, but it is not known to affect 
noradrenalme-induced vascular contraction of 
smooth muscle to a clinically significant degree The 
haemodynamic and hormonal effects of a single sub­
lingual dose of nifedipine 20 mg in 8 moderately hy­
pertensive patients have been studied before and 
during postsynaptic alphaj-blockade with prazosin 
The antihypertensive effect of nifedipine was signifi­
cantly increased by prazosin pretreatment (fall in 
mean arterial pressure 60 min after nifedipine 
— 16 7% with and —8 5% without prazosin), despite 
similar increases in plasma noradrenaline Prazosin 
alone caused no change in supine blood pressure for 
2 h after an oral dose of 2 mg The findings are in 
keeping with the hypothesis that prazosin blocks a 
compensatory reaction to vasodilatation caused by 
nifedipine 
Keywords: nifedipine, prazosin, hypertension, al-
phapadrenergic blockade, calcium antagonism, va­
sodilatation, plasma noradrenaline 
Elevated peripheral resistance, partly caused by aug­
mented vascular smooth muscle tone, is a common 
feature of most types of hypertension Calcium an­
tagonists like nifedipine can lower the increased 
smooth muscle tone [1,2] The blood pressure lower­
ing effect of nifedipine is attenuated by reflex stimu­
lation of the sympathetic nervous system [3], leading 
to release of noradrenaline into the synaptic cleft and 
an increase in vascular smooth muscle tone via post­
synaptic alpha adrenoceptor stimulation Recent 
pharmacological studies in animals [4,5] and man [6, 
7] have pointed to the possibility that noradrenaline 
can activate vascular smooth muscle cells not only 
via postsynaptic alpha,-adrenoceptors, but also via 
postsynaptic alpha2-receptors Stimulation of the al-
phaj-receptors may be inhibited by calcium antago­
nists These agents have a much smaller inhibitory 
action on postsynaptic alphai-receptors [4, 8] Thus, 
prazosin, which preferentially blocks alpha,-recep-
tors, should increase the antihypertensive effect of 
nifedipine [8] Therefore, the acute antihypertensive 
effect of nifedipine before and during alphai-block-
ade with prazosin has been studied in 8 patients with 
moderate hypertension 
Patients and Methods 
Eight patients, 7 males and 1 female, aged 
20-66years (mean 42 years) participated in the 
study Six patients had essential hypertension and 
normal renal function and 2 had renal hypertension 
with endogeneous creatinine clearances of 14 and 
18 ml/min In patients already being treated for hy­
pertension, all antihypertensive drugs were discon­
tinued for at least 3 weeks before the start of the 
study All patients whilst untreated had an outpatient 
diastolic blooc pressure of at least 110 mmHg 
The study protocol consisted of two parts First 
the antihypertensive action of sublingual nifedipine 
20 mg (capsule formulation) was determined After 
at least 2 days a second 20 mg dose of nifedipine was 
given, 2 h after a single oral dose of prazosin 2 mg 
Dunng the experiments the patients remained su­
pine, in a quiet room, from 8 a m till noon No food 
or dnnk was given Blood pressure (BP) and heart 
rate (HR) were measured every 2 mm by an automat-
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ГаЫе 1. Changes m blood pjrjmelers 60min after nifedipine 
alone 
Haemoglobin 
[mmol' l] 
HaenlJlocnt ["«] 
ГоіаІ Protein [g 'IJ 
Albumin [g/l] 
PRAIng ml/h) 
Aldosterone 
[ng 100 ml] 
Adrenaline 
Inmol' l] 
Noradrenaline 
[nmol/l] 
Belore mfedipmc 
7 7 3:0 7 
47(1 ± 1 2 
59 5 ± 3 2 
350 + 2 8 
1 13 ± 0 37 
128 ± 1 5 
022 + 0 05 
I 6 9 ± 0 1 6 
After nifedipine 
8 5 ± 0 6 
4« 5 ± 3 0 
66 8 ± 2 4 
386 ± 2 4 
I 8 5 ± 0 6 3 
100 ± 1 9 
031 ± 0 0 8 
4 86 ±0.65 
/><0001 
/ x O O l 
/><«00l 
/ ) < 0 0 0 l 
η s 
η s 
p<Q0ì 
p<00\ 
Tabic 2. ('hanges m blood parameters 60 mm after nifedipine giv-
en 2 h after prazosin 
Haemoglobin 
[mmol/l] 
Hacmatocnt]".)] 
Tola! Protein [g/l] 
Albumin [g/l] 
PRAlng/ml/h] 
Aldosterone 
[ng/l()0ml] 
Adrenaline 
[nmol/l] 
Noradrenaline 
[nmol/l] 
Before nifedipine 
77 ± 0 6 
369 ± 2 8 
59 9 ± 2 9 
34 8 ± 2 6 
1.22 + 035 
115 ± 2 5 
0 25 + 005 
3 55 ± 0 42 
After nifedipine 
81 ± 0 6 
386 ± 2 9 
62 8 ± 1 2 
360 ± 2 6 
IK5±055 
106 ±3.6 
0 4 4 ± 0 0 7 
6 58 ± 0 85 
/><0001 
p < 0 0 l 
/><002 
p<002 
n.s. 
η s. 
^ < 0 0 l 
p < 0 0 1 
ic recorder (Arteriosonde 1225). When BP had stabi­
lized after 30 min of supine rest, the mean value of 
5 consecutive readings (calculated every 15 min) was 
used for analysis. Mean arterial blood pressure 
(MAP) was calculated as the sum of the diastolic 
blood pressure and one third of the pulse pressure. 
Blood samples were taken before and 60 min af­
ter the administration of nifedipine via an indwelling 
venous catheter inserted 45 min before each experi­
ment. They were used for the determination of hae­
moglobin, haematocrit, total protein, albumin, plas­
ma renin activity (PRA; [9]), aldosterone [10], nor­
adrenaline and adrenaline [11]. Before and after each 
expenment the supine and standing blood pressures 
were measured by routine sphygmomanometry (Er-
kameter 300). The study protocol was approved by 
the local Ethical Committee. All patients gave their 
informed consent to the experiment. 
Statistical comparisons were made by Student's 
/-test for paired observations. Changes in hormonal 
parameters were examined by the Wilcoxon's rank-
sum test. Correlations were calculated according to 
Spearman A p-level of 0 05 (two-tailed test) was 
considered to be the level of statistical significance. 
All values are given as mean ± SEM. 
Results 
Acule Effects of Nifedipine Alone 
Nifedipine 20 mg administered as a single agent 
lowered blood pressure from 156/107 ± 8 / 6 to 
148/93 ± 7 / 3 mmHg at 60 mm. The mean maximal 
decrease in MAP(— 10,6 ± 3,5° n) was seen at 30 mm 
(Fig. 1). MAP was below the pretreatment level from 
15 to 75 min after nifedipine administration. A sig­
nificant inverse correlation was found between the 
maximal decrease in MAP and the pretreatment 
MAP level (r= -0.74, ρ <0.05) The heart rate rose 
over 60 mm by 26.1 ±4.6%, from 71 ± 4 to 88 ± 
4 beat min. The blood levels of haemoglobin, haema­
tocrit, total protein and albumin all rose significantly 
by about 12% (lable 1). Plasma catecholamine levels 
rose. PRA level did not change significantly, nor did 
aldosterone, sodium or potassium. No correlation 
existed between the observed rise in plasma nor­
adrenaline and the changes in MAP and HR. Mean 
blood pressure 120 min after nifedipine was similar 
in the supine and standing positions (118.2±3.0 and 
118.4±4.2 mmHg). Side effects consisted of head­
ache (n= 4), flushing (η =4), palpitations (л = 3) and 
orthostatic dizziness (n = 3). 
Acute Effects of Nifedipine After Prazosin 
Blood pressure was not significantly altered by pra­
zosin (beforehand 151/107±6/5mmHg and after 
2 h 155/109±6/3 mmHg). A reduction in MAP of 
more than 5% was found in only 3 patients and it had 
disappeared within 90 mm. Prazosin did not cause 
any change in HR. Two hours after prazosin the lev­
els of all blood parameters measured were no differ­
ent from those before treatment with nifedipine on 
the first study day (Tables 1,2), the sole exception be­
ing a higher level of plasma noradrenaline (3.55 ± 
0.42 vs1.69±0.16nmol/l;/7<0.01). 
Nifedipine given 2 h after prazosin lowered 
blood pressure more than without the pretreatment 
(Fig. 1); the difference was significant from 45min 
after its administration. All patients reached an al­
most normoiensive level; at 60min, BP had fallen to 
139/84 ± 7/3 mmHg. The mean maximal decrease in 
MAP was —21.2±2.1%. In these experiments no 
correlation was found between the maximal de­
crease in MAP and pretreatment MAP. Given after 
prazosin, nifedipine induced a nse in HR of 
18 
mean a ter a 
0-] 
10 
2 0 
% η 
h e a 
3 0 
2 0 -
1 0 -
t 
\l 
к 
\ 
crease 
rate 
v 
/ 
/ 
p r e 
\U 
3sure 
1 
* 
4 
Í 
/ 4 
Ί X 
r 
-^L_ 
r— 
τ О 
0 - - о 
* * ** 
"'"-^  
" - î 
i ¡ i 
J 
1 
η θ 
30 SO 90 
1 me(rr η) 
Fig 1 Changes in MAP and HR (теап±ЧЬМ) after nifedipine 
20 mg before (open symbols) and after prclcatment with prazosin 
2 mg ρ о (closed symbols) *Significance ol différence belween 
the two treatments »/)<00S ""¿KOOI 
+ 243±5 30/o at 60min, from 72±3 to 91 ± 
5 beats/mm The rise was no different from that ob 
served after nifedipine alone (big 1) The levels of 
haemoglobin, haematocnt, total protein and albu 
min rose significantly (by about 5% Table 2) but to a 
lesser extent than after nifedipine alone {p < 0 05 for 
all) The rise in plasma noradrenaline level after 
nifedipine was the same whether or not prazosin 
pretreatment was given ( + 3 2±0 6 and 3 0± 
0 5 nmol/l) The rise m plasma adrenaline ( + 0 19 ± 
0 05nmol/l), too, was not significantly different 
from that after nifedipine alone ( + 0 09± 
0 02 nmol/l) After pretreatment with prazosin, m 
fedipine caused no significant change in the PRA, al 
dosterone, sodium or potassium levels Side-effects 
consisted of headache and flushing in 3 patients, pal 
pitations m 2, and orthostatic dizziness in one 
Again, the mean blood pressures 120 mm after mfed 
ipine were not significantly different in the supine 
and standing positions (110 2±3 9 and 103 5± 
4 0 mmHg, /; = 0 07) The haemodynamic effects of 
nifedipine and prazosin in the patients with a low en-
dogenous creatinine clearance were comparable to 
those in the patients with normal renal function 
Discussion 
The acute effects on BP and HR of nifedipine alone 
reported here agree with those reported previously 
[3, 12, 13] Like others [14, 15], the magnitude of the 
fall in blood pressure caused by nifedipine was 
found to be related to the pretreatment level After 
nifedipine alone, BP was not lowered to an entirely 
normal level Reflex sympathetic stimulation 
through neuronally released noradrenaline [16 18] 
may well be one of the factors antagonizing the va-
sodilator effect of nifedipine through stimulation of 
the vasoconstrictor postsynaptic alphai-receptors on 
vascular smooth muscle cells Experimental data ap-
pear to indicate that nifedipine in therapeutic con-
centrations is not likely to affect alpha,-adrenocep-
tor mediated vasoconstriction to a significant de-
gree [4, 8] Indeed, blockade of the alpha, receptors 
by prazosin appeared to enhance the antihyperten-
sive effect of nifedipine in our patients 
A double blind cross over study design was not 
employed because it was feared that a severe fall in 
blood pressure might occur [4,6, 19], especially since 
a fairly high dose of nifedipine was given [13] Never 
theless, it is considered that the conclusions are still 
valid because of the objective nature of the study pa-
rameters, which would have excluded observer bias 
The fixed order design could not have been responsi-
ble for part ofthe greater hypotensive effect of mfed 
ipine after prazosin in pretreatment, since in 11 other 
hypertensive patients the hypotensive effect of a sec-
ond dose of nifedipine was the same as that of the 
first dose given one or more days previously (unpub-
lished observations) 
Although a control study was not performed, 
during which the actions of prazosin alone would 
have been studied for a period of 4 h, it is not likely 
that the enhancement was due to an enhanced effect 
of prazosin on blood pressure Data from the litera-
ture suggest that, after a single oral dose of prazosin, 
the maximal decrease in supine blood pressure in hy-
pertensive patients occurs within 2 h [20, 21], and that 
the plasma prazosin level also peaks at around the 
same time [20, 22, 23] On the other hand, the reduc-
tion in postsynaptic alpha, receptor blockade after a 
single oral dose persists for a longer period Pitter-
mann et al [23], using phenylephrine infusions as the 
stimulus, still found a reduction in postsynaptic al-
pha, reactivity 5 to 7 h after a single oral dose of pra-
zosin, ι e more than 3 h after the plasma prazosin 
levels had begun to decline Therefore, the greater 
acute hypotensive effect of nifedipine after prazosin 
pretreatment is most likely to be due to diminished 
postsynaptic alphai-reactivity and not to an addi­
tional direct hypotensive effect of prazosin itself Jee 
19 
and Opie [19] warned against injudicious nifedipine 
therapy in patients already being treated with pra­
zosin, because of the possibility of a severe drop in 
blood pressure in the standing position. Although se­
vere orthostatic hypotension was not seen in the 
present patients, we feel that the warning is still justi­
fied in the light of the present data. 
As might be expected of a drug with a vasodilat­
ing action [24], the acute antihypertensive effect of 
nifedipine was accompanied by an increase in HR 
[13, 17]. Despite the greater fall in BP after pretreat­
ment with prazosin, the increase in HR after nifedi­
pine was similar to that without such pretreatment. 
One possible explanation would be diminished sen­
sitivity of the baroreceptor reflex arc caused by pra­
zosin [25]. This might also explain why the absolute 
rise in plasma noradrenaline level was no greater af­
ter nifedipine with prazosin pretreatment than after 
nifedipine alone. Plasma adrenaline levels did not 
show major changes, which is in accordance with 
other studies of the acute effects of calcium antago­
nists [17,18,26] In contrast to our previous observa­
tions [13], PRA levels did not rise significantly after 
nifedipine. However, the number of patients studied 
here was small. On the other hand, reports on the ef­
fect of nifedipine on PRA are conflicting [12, 27]. As 
expected [13, 17, 27], plasma aldosterone levels did 
not increase after nifedipine, possibly because an­
giotensin H-mduced aldosterone secretion from the 
adrenal zona glomerulosa is inhibited by calcium an­
tagonists, as has been shown in vitro [28, 29] and in 
vivo [30]. 
As in a previous study [13], nifedipine was found 
to produce a rise in haemoglobin, haematocrit, total 
protein and albumin concentrations, which might be 
explained by a decrease in plasma volume caused, at 
least in part, by the acute diuretic effect of dihydro-
pyndine derivatives [3,12, 26, 31]. The fact that the 
diuretic effect seemed to be less when the decrease in 
blood pressure was greater after prazosin pretreat­
ment could be explained by a decrease in pressure 
diuresis [32]. 
The relevance of the data presented to chronic 
treatment of hypertension requires further study. A 
satisfactory reduction in blood pressure on long-
term treatment with a combination of nifedipine and 
prazosin was observed in six of the patients in the 
study. 
In conclusion, the alphai-adrenoceptor blocker 
prazosin was found to enhance the acute antihyper­
tensive effect of nifedipine. This is in agreement with 
the concept that the vasodilator effect of nifedipine 
is antagonized by reflex stimulation of the sympa­
thetic nervous system. 
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Treatment of a phaeochromocytoma 
of the urinary bladder with 
nifedipine 
Calcium channel blockers could be useful ш the treatment of a 
phaeochromocytoma ' In this repon we describe the effects of 
nifedipine m a patient with a phaeochromocytoma of the uruury 
bladder which caused severe rises in blood pressure as a result of 
mechanical stimulation during voiding. 
Caie report 
A 23 year old woman « i t referred beauté of hypmenaoo Fot ыж y o n 
the had oonccd that іе ете headache, blurred visioo, oauiea, and pallor 
always occurred immediately after voiding Extenuve lovemgauon con­
firmed the pretence of • phaeochromocytoma of the wall of the urinary 
bladder At reti plasma noradrenaline amceotnuoD w i t mcreucd to 
14 0 nmol/1 (2369 Dg/1. twraul (SD) 1 42 (0-61) nmol/1 (240 (103) ng/1)) but 
plamu adrenaline conccntnuon wi t normal (0 13 nmol/1 (24 ng/l), normal 
0*17 (007) nmol/1 (31 (13) ngli)) Before surgical removal of the nunour 
aeven ехрепшаіп were performed with informed contení 
On day 1 the effects of mictunnon on blood pressure and plasma 
eatecboUmma were tradied without trcatmait ( M l ) and after one sub-
lingual dote of 10 mg nifedipine (M2, 3, 4) After one week of treatment 
with nifedipine 10 mg three times daily, another е ж р е т т а и wat performed 
( M l , 6, 7), accompanied by a throbbing headache, nautea, and pallor 
Acute treatment (M3 and 4) and treatnient for one week with nifedipine 
prevented both the severe m e in blood pressure and all accompanying 
•ymptomt, despite similar rises in plasma mecholamme* and unchanged 
unnary excrenon of noradrenaline over 24 hours The noradrenaline con-
с е п т і ю п wis 126 omol/mmo) creatinine and bearne 131 п т о Ь т т о ) 
creatinine (nomili 5-34) ViniUylmandehc l a d concentration measured 
4 1 nmol'mmol creatinine and afterwirds became 4 8 nmol/mmol creatinine 
(normal 1 2-4 5) 
Comment 
Our case report shows that an agent which blocks the entry of 
calcium сяп prevent severe hypertensive spells which are provoked 
by the mechanical stimulation of a phaeochromocytoma 
This patient provided an excellent oppomuuty to study the affect 
of nifedipine because the rise in blood pressure and plasma catecho­
lamine concentrations could be reproductbly provoked by micmrition 
Acute and hebdomadal treatment with nifedipine prevented the steep 
rise in systolic and diastolic blood pressure The high systolic blood 
pressure nse after the sublingual dose of 10 mg might be explained 
by the short interval between the nifedipine dose and M2. 
The complete absence of a rise in blood pressure after experiments 
МЭ and M4 might be explained by one of three mechanisms exhaus­
tion of the release of noradrenaline from the tumour as a consequence 
of the repeated contractions of the bladder within a short urne, 
Time (mnulesl 
BO 202 П0 X ¿5 60 15 30«) 60 75 90ЮО 
Before DfTT) Two days alter 
wthdnftwl o* 
nifedipine 
Dettiti of blood prenure, heart rate, and 
plasma aiccbolunmcs (log *calc) before and 
after mictuntioa (M) 
(M5) A control experiment was performed two days after stopping nifedi­
pine (M6 and 7) In every experiment the patient voided spontaneously 
in the supine potinon No other médication was used Before and every 
two minutes after each micturition blood pressure, heart rate, and plasma 
catecbolaminei' were measured Unnary excretion of catecholamine· over 
24 hours and vaniUyUnandelic and content were measured twice both 
before and during the last two days of treatment with nifedipine 
Without nifedipine, micninnon provoked a steep m e in blood pressure 
inhibition of the release of noradrenaline from the tumour by nifedi-
pine as suggested by Serfas tt ai1, or interference of nifedipine with 
the апмп of noradrenaline on the blood vessels and hean The 
fint possibility is rendered less likely by the persia tend у strong 
increments of plasma noradrenaline two days after stopping nifedipine. 
The increase in plasma noradrenaline after experiment MS and the 
unchanged excretion of catecholamines over 24 hours after heb-
BMJ/U47/8SÌ4 COPTIIGHT © l»} ALL RIGHTS Of REPRODLCTtON OF THIS REPRINT ARE RESFHVEO IN ALL COUNTRIES OF THE WORLD 
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denudai treatment with nifedipine strongly deny the case for the 
second possibility. 
The third possibility is the most likely. An attenuated pressor 
response to cxogeootu noradrenaline has been observed dunng 
treatment with mfediptne in normotensive patients.1 Our patient 
who had very high plasma noradrenaline concentrations after micturi-
tion showed a total abobuon of the blood pressure response after 
experiments M3, M4, and M5. This might be explained by the 
exhaustion of intracellular calcium stores due to chronic CEposure to 
the high circulating noradrenaline concentrations when the agent to 
block calcium influx has taken effect * 
It is most likely that the steep increases in blood pressure in our 
patient were prevented by the effect of nifedipine on the target organ 
—that is, vascular smooth muscle. 
We thank Dr R Wevers of the neurology laboratory for hn technical help 
and Ineke ten Have, who helped prepare the manuscript 
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cirdiomyopathy afipareni supprntion of symptôme and noradrenaline tec ret ion 
by calcium channel blockade Lùnctt 1983,и 711-3 
2 Hoffmann JJML. WiUemien JJ, Thien Th, Bcnraad ThJ Radioenzycutic aauy 
ol pluma adrenaline and noradrenaline evidence tor a <.,OM 1 inhibniM 
Гачиг associated with essential hypenenston Clin Chim Ada 1902,128 319-27 
1 Beretta-PiLCoh С , Bianchetti MG, Weidmann Ρ, Boehringer К. Link L, Morion 
JJ E (Те с» of acute mild hypercalcemia or oí the calcium antagonist nifedipine 
on cardiovascular responsivenest 10 norepinephrine or angioicntine II in 
normal humans JCardttnau Pharmacol 1902,4 306-12 
4 Saida K, Van Bréeme η С A possible Ca' -induced (la1* releue mechanism 
mediated by norepinephrine in vascular smooth muscle Pfluttn Arch 1981, 
397 166-7 
(Atcepied 6 Fthmary 1985) 
Division of General InteroAl Medicine and Division of Nepbrology, 
St Radboud Hospital, tieert Grootepleio Zuid θ, 6525 GA Nl |mcgen, 
The Netherfandt 
J W M L E N D E R S , MD, consultant internist 
H E S L U I T E R , MD, consultant internist 
Th T H I E N , MD, consultant internist 
Department of Experimental and Chemical Endocrinology, S i 
Radboud Hospital, Geert Grootepleln Zuid β, 8525 GA Xl lmegen 
J W I L L E M S E N , senior laboratory scientific officer 
Correspondence to D r J W M Lenders 
26 
CHAPTER IV 
THE TREATMENT OF HYPERTENSIVE EMERGENCIES WITH INTRAVENOUS FELODIPINE 
H.E. Sluiter, F.Th.M. Huysmans, J.F.M. Wetzeis, Th.A. Thien*, 
and R.A.P. Koene 
Department of Medicine, Divisions of Nephrology and General Internal 
Medicine*, Sint Radboud Hospital, University of Nijmegen, The Netherlands 
Published in part ins Drugs (1985) 29 (Suppl.2): 144-153, from which Fig.2 
and Fig.3 were reproduced by permission. 
Copyright 1985: ADIS Press Ltd. 
SUMMARY 
Nine patients with a hypertensive emergency and a pretreatment blood pressure 
of 205/134 + 9/7 mmHg (mean + SEM) were treated with an intravenous infusion 
of the dihydropyridine calcium antagonist felodipine at a starting rate of 
0.035 + 0.009 mg/min. Felodipine (total dose administered: 0.019+0.003 mg/kg) 
caused a lowering of blood pressure to a lowest mean value of 146/90 ± 9/8 
mmHg after 45 min. In all patients symptoms of headache, hypertensive 
encephalopathy, or left ventricular failure improved already during felo-
dipine infusion. In only one patient the infusion of felodipine had to be 
interrupted because of a vasovagal reaction. In individual cases there was a 
close relationship between felodipine plasma levels and its antihypertensive 
effects (r=-0.84 to -0.99). Intravenous felodipine is an attractive alterna-
tive regimen for the management of a hypertensive emergency. 
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INTRODUCTION 
In hypertensive emergencies, total peripheral vascular resistance is grossly 
elevated. Therefore, arteriolar vasodilators are a reasonable therapeutic 
choice in the initial treatment of this life-threatening disorder. Calcium 
antagonists, especially dihydropyndine derivatives, are rapidly gaining 
ground as antihypertensive drugs (1). They cause a relaxation of vascular 
smooth muscle due to an interference with cellular calcium metabolism (2,3). 
The dihydropyndine nifedipine is safe, and in many cases effective, when 
given as a single oral or sublingual dose to patients with a hypertensive 
emergency (4,5). A disadvantage of nifedipine is its degradation by exposure 
to daylight, making the intravenous administration of the drug technically a 
cumbersome procedure. Especially in a hypertensive emergency, the slow intra-
venous infusion of a vasodilator in the management of the acute episode is 
the preferred route of administration as the dose infused can be titrated 
against the observed effects. Thus a too rapid fall in blood pressure leading 
to an increased risk of complications due to myocardial and cerebral hypoper-
fusion can be avoided (6,7,8). The dihydropyndine felodipine is not sensi-
tive to exposure to daylight and is a clinically effective antihypertensive 
drug in plasma concentrations tenfold lower than nifedipine. In vitro, it has 
less depressant activity on the heart than nifedipine (9). Felodipine has ve-
ry powerful antihypertensive effects (10,11), also in patients with hyperten-
sion of renal origin (12), which is a relatively frequent cause of a hyper-
tensive crisis. Here, we present our favourable results with the slow intra-
venous infusion of felodipine in nine patients with a hypertensive crisis. 
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PATIENTS AND METHODS 
Clinical characteristics of the patients studied are given in Table I. We 
treated nine patients with a hypertensive emergency and a pretreatment blood 
pressure of 205/134 + 9/7 mmHg (mean + SEM) with intravenous felodipine. 
Eight of them had a hypertensive crisis, defined as the presence of a diasto­
lic blood pressure above 130 mmHg with grade III or grade IV hypertensive re­
tinopathy (according to Keith et al (13)), or as the presence of a diastolic 
blood pressure above 100 mmHg accompanied by clear signs of a hypertensive 
encephalopathy (14). One patient did not satisfy the abovementioned crite­
ria. She had experienced a hypertensive crisis that was treated successfully 
with nitroprusside and nifedipine, but the subsequent reappearance of fresh 
retinal haemorrhages, when blood pressure rose again despite continued anti­
hypertensive therapy with metoprolol, furosemide, nifedipine, and Captopril 
prompted us to use intravenous felodipine. During the treatment of their hy­
pertensive emergencies, the patients rested in the supine position from 45 
m m before until 4 h after the start of felodipine infusion. Supine blood 
pressures and heart rate were measured at 2 m m intervals with an automatic 
recorder (Artenosonde 1225). In five patients, forearm blood flow (FBF) 
measurements were made with mercury strain gauge plethysmography, using a 
pulse cuff to exclude the circulation of the hand. 
Table I. Clinical data of 9 patients with a hypertensive emergency 
Antihypertensive 
treatment in 
previous 4Θ h 
Sex Age PretreaLment Fundoscopic Hypertensive Cause of 
blood pressure changes" Encephalopathy hypertension 
(iiMiHg)a 
Fndogenous 
creatinine 
clearance 
(тІ/тіп/ІЛЭт2) 
•>1 
199/132 
221/1)0 
F 38 240/165 
F 22 159/101 
M 17 181/132 
M 18 196/142 
Г 23 187/105 
F 35 218/157 
F 53 240/144 
ΠΙ 
IV 
IV 
III 
III 
IV 
IV 
essential 
renal artery 
stenosis 
essential 
haemolytic uremic 
syndrome 
chronic rejection 
of kidney 
transplant 
essential 
haemolytic uremic 
syndrome 
essential 
eaeential 
109 
58 
55 
5 
2Θ 
128 
10 
58 
149 
Atenolol 
Chlortalidone 
NiTedipine 
Furosemide 
Nifedipine 
Metoprolol 
furosemide 
Nifedipine 
Metoprolol 
Nifedipine 
Diazoxide 
None 
Metoprolol 
Furosemide 
Ni fedipine 
Captopril 
None 
a) mean of 5 Artenosonde readings at 2 min intervale after 45 min supine reat 
b) according to Keith et al (13) 
Felodipine was infused through an indwelling intravenous catheter in an ante-
cubital vein in a total dose of 0.01 to 0.04 mg/kg (mean 0.019 ± 0.003 
mg/kg). The infusion period ranged from 20 to 120 m m (mean 57 ± 11 m m ) . The 
mean starting infusion rate was 0.035 + 0.009 mg/min (range 0.01-0.08 
mg/min). In the course of the study the starting infusion rate of felodipine 
was gradually diminished from 0.08 to 0.01 mg/min as lower infusion rates ap­
peared to be as effective in controlling blood pressure, but in a more gra-
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dual way. In five patients the rate of infusion was halved, once a satisfac-
tory reduction in blood pressure was achieved. Blood samples for the determi-
nation of felodipine plasma levels were taken at 40 min intervals from the 
start of the infusion through a second indwelling antebrachial venous cannu-
la. Plasma renin activity (PRA (15)), aldosterone, Cortisol (16), adrenaline 
and noradrenaline levels (17), and plasma free ionized calcium levels (ICA 
analyzer, Radiometer, Copenhagen) were measured in venous blood before, and 
30 and 120 min after the end of the felodipine infusion. In five of the pa-
tients plasma antidiuretic hormone levels were measured at the same intervals 
(Vasopressin RIA-kit, Bühlmann Lab Ltd, Basel, Switzerland). 
For statistical calculations the mean values of 5 consecutive blood pressure 
and heart rate readings were used at 15 m m intervals. Mean arterial pressure 
(MAP) was calculated as the diastolic blood pressure plus one third of the 
pulse pressure. For FBF values also the mean of analyses of 5 curves was us-
ed. Forearm vascular resistance (FVR) was defined as MAP/FBF, and expressed 
in arbitrary units. Statistical calculations of haemodynamic parameters were 
made with Student's t-test for paired observations. Hormonal data were ana-
lysed with Wilcoxon's rank-sum test. Correlations were calculated according 
to Spearman. A p-value of less than 0.05 was considered to be of statistical 
significance. Unless indicated otherwise, all data are given as means +_ SEM. 
The study protocol was approved by the Ethical Committee of the Sint Radboud 
Hospital. All subjects gave written informed consent to participate in the 
study. 
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RESULTS 
The haemodynamic effects of felodipine are shown in Figure 1. Felodipine lo­
wered blood pressure from 205/134 + 9/7 mmHg to a lowest mean value of 146/90 
+ 9/8 mmHg (-31.8±3.95ί) after 45 min. No further decrease in blood pressure 
was seen after the infusion of felodipine was stopped. In two patients a se­
cond infusion (0.02 mg/kg) had to be given, because diastolic blood pressure 
rose again to values above 130 mmHg, 100 and 120 min after the end of the 
first infusion respectively. For the same reason, a third patient received 
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Figure 1. Effects of intravenous felodipine on blood pressure and heart rate 
(means ± SEM) in 9 patients with a hypertensive emergency. 
Felodipine was infused at a starting rate of 0.01 to 0.08 mg/min 
from t=0 m m during 57 ± 11 m m . 
32 
oral felodipine (5 mg) 60 min after the end of the infusion. During the infu-
sion, heart rate rose from 86 + 7 to 98 + 6 beats per m m after 30 min, but 
had returned to levels not significantly different from baseline 60 min after 
the start of the infusion. In all five patients where it was measured, felo-
dipine caused a rise in forearm blood flow (from 1.9 + 0.2 ml/min/100 ml to 
5.7 + 0.8 ml/min/100 ml).Forearm vascular resistance decreased by 79 + 5% 
(from 80.5 + 10.8 to 18.2 + 4.8 units). 
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Figure 2. Haemodynamic effects of felodipine infusion (0.02 mq/kq over 60 
min) in a previously untreated patient with a hypertensive crisis. 
The infusion rate of felodipine was halved after 20 m m . 
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In all patients the highest plasma levels of felodipine (ranging from 11.2 to 
67.0 nmol/l, mean 31.4 ± 6.0 nmol/1) coincided with the observed maximal an­
tihypertensive effect. A representative example of the haemodynamic effects 
in a single patient is shown in Figure 2. In this previously untreated pa­
tient, as in the others, the antihypertensive effect of the drug could be ti­
trated by adjustment of the infusion rate. In the 5 patients where the infu­
sion rate was halved, the antihypertensive effect and the plasma levels of 
felodipine remained stable during the second part of the infusion. In Figure 
3, the correlation between log plasma concentrations of felodipine and the 
percentua] decrease in mean arterial pressure is shown for another patient. 
-40 
Δ MAP (·/.) 
Figure 3. Relationship between the log felodipine piasma concentration (log 
Cp) and the observed changes in mean arterial pressure (ΔΜΑΡ) in a 
patient with malignant hypertension. 
The correlation between the changes in mean arterial pressure and log plasma 
concentrations was very strong. In individual cases, correlation coefficients 
varied between -0.B4 and -0.99. Felodipine did not cause important changes in 
hormonal parameters or in plasma ionized calcium (Table II). 
Signs of deteriorating cerebral perfusion or anginal complaints were not ob­
served during the infusion. Felodipine infusion had to be interrupted prema­
turely in only one patient. In this patient, the only one who presented with 
a hypertensive crisis and left ventricular failure, blood pressure decreased 
gradually from 240/144 to 201/115 mmHg during 30 min infusion of felodipine 
(0.01 mg/min) , while heart rate rose from 92 to 101 beats per m m and her 
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Table II. Changes in hormonal parameters during felodipine infusion in 9 pa­
tients with a hypertensive emergency8 
Before 30 min after 120 min after 
end of infusion end of infusion 
PRA (ng/ml/h) 
Aldosterone (ng/100 ml) 
Adrenaline (nmol/L) 
Noradrenaline (nmol/L) 
Cortisol (μπιοΐ/ΐ) 
Antidiuretic hormone 
(pg/ml, nr5) 
Plasma ionized calcium 
(mmol/l) 
a) means +_ SEM 
b) p<0.05 
symptoms disappeared. However, after 40 min infusion of felodipine, blood 
pressure dropped suddenly to 120/82 mmHg with a concomitant fall in heart 
rate to 68 beats per m m . At the same time the patient noticed increasing 
dyspnea. The infusion of felodipine was stopped and the patient recovered 
within a few minutes without further therapeutic measures. Other side effects 
were minor, and consisted of flushing in six, and headache in three pa­
tients. During the infusion of felodipine symptoms of hypertensive encephalo­
pathy disappeared in all six patients who presented with this condition. 
After the successful management of their hypertensive emergency, oral felo­
dipine therapy could be instituted in all nine patients, without loss of 
blood pressure control. During the first week of treatment renal function was 
not influenced by felodipine (plasma creatinine levels 302 +_ 129 μηοΐ/ΐ be­
fore, and 2 7 4 ^ 124 μΐηοΐ/ΐ, one week after the initiation of felodipine). 
16.7 + 6.4 
30.2 + 10.8 
0.54 + 0.13 
2.92 + 0.87 
0.46 + 0.12 
14.3 + 7.3 
1.19 + 0.01 
19.7 + 7.6 
30.9 + 9.6 
0.59 + 0.14 
3.64 + 0.96 
0.74 + 0.15b 
15.4 + 7.6 
1.22 + 0.02 
15.0 + 12.1 
36.6 + 18.1 
0.62 + 0.25 
2.32 + 0.53 
0.68 + 0.19 
13.9 + 10.9 
1.19 + 0.02 
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DISCUSSION 
In patients with a hypertensive emergency, acute treatment is required in or-
der to prevent serious or even life-threatening complications (18,19). In our 
study, felodipine, infused intravenously at a rate of 0.01 to 0.0B mg/min, 
was very powerful in lowering blood pressure in nine patients with this dis-
order. Felodipine was effective even in cases where previous treatment with 
drugs such as nifedipine, diazoxide, or Captopril had failed to control their 
hypertension (Table I). The strong relationship that was found between plasma 
concentrations of felodipine and the change in mean arterial pressure sug-
gests that the magnitude and the steepness of the fall in blood pressure can 
be titrated by adjustment of the infusion rate. Like in the patient shown in 
Figure 2, the desired lower level of blood pressure was maintained when the 
infusion rate was halved in four other patients. As may be expected from a 
vasodilator drug, the fall in blood pressure achieved with felodipine was ac-
companied by a compensatory rise in heart rate which, however, was tempora-
ry. 
In this study we did not find increases in plasma levels of noradrenaline and 
PRA, in spite of the pronounced fall in blood pressure due to vasodilation 
(20). This contrasts with the rise generally seen in normotensive subjects 
and moderately hypertensive patients after felodipine administration 
(21,22). The most likely explanation appears to be the relatively high pre-
treatment levels of the hormonal parameters shown in Table II. Furthermore, 
six of our patients had received other antihypertensive drugs in the 48 h be-
fore felodipine, which may have also prevented a rise in PRA and catecholami-
ne levels during felodipine therapy. 
The only severe side effect of felodipine occurred in our last patient. We 
feel that a sudden and extreme vagal reaction was the most likely explanation 
of this adverse reaction. We do not know what has caused this reaction, but 
we have incidentally seen similar reactions to the acute administration of 
the vasodilators nifedipine, diazoxide, and prostacyclin. 
In conclusion, felodipine caused a considerable reduction in blood pressure 
in nine patients with a hypertensive emergency. Felodipine was even effective 
in patients resistant to other potent vasodilators. Despite this very strong 
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vasodilatory effect a gradual fall in blood pressure could be achieved safely 
with a slow intravenous infusion of felodipine. Apart from a vagal reaction 
in one patient, no serious side effects were observed. Felodipine is a very 
attractive drug for the management of patients with hypertensive emergen­
cies. An important feature of the treatment was the effective switch to oral 
maintenance therapy with felodipine, which could be made in all nine patients 
without loss of blood pressure control. 
Acknowledgements: This study was supported by a grant (С 81.286) from the 
Dutch Kidney Foundation and by AB Hässle, Mölndal, Sweden, who also supplied 
the felodipine used in our studies. 
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ANTIHYPERTENSIVE AND BIOCHEMICAL EFFECTS OF THE DIHYDROPYRIDINE FELODIPINE IN 
THE CHRONIC TREATMENT OF MODERATE TO SEVERE HYPERTENSION 
H.E. Sluiter, F.Th.M. Huysmans, Th.A. Thien*, and R.A.P. Koene 
Department of Medicine, Divisions of Nephrology and General Internal 
Medicine*, Sint Radboud Hospital, University of Nijmegen, The Netherlands 
SUMMARY 
Twenty-seven patients with moderate to severe hypertension, in 19 cases ac-
companied by renal failure, were treated with oral felodipine, a new dihydro-
pyndine calcium antagonist. Twenty-three patients completed a 24-, and 19 a 
48-week follow-up. At the end of follow-up felodipine was given in combina-
tion with a beta-adrenoceptor blocking drug in most (80«) instances, but in 
60% of the cases no diuretic was needed. Antihypertensive treatment with fe-
lodipine caused a lowering of blood pressure of 25%, which was sustained 
throughout follow-up. The drug was well tolerated. Felodipine was equally ef-
fective in patients with renal insufficiency and in patients with normal re-
nal function. Plasma creatinine levels remained stable throughout follow-up. 
Plasma levels of ionized calcium rose during felodipine therapy. This finding 
could not be related to the change in blood pressure or to the use of thiazi-
de diuretics. Our data confirm the potency of felodipine in the chronic 
treatment of hypertension. 
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INTRODUCTION 
In most hypertensive patients, the level of blood pressure is related to an 
increase in total peripheral resistance caused by an augmented vascular 
smooth muscle tone, which is critically dependent on intracellular free cal­
cium concentrations (1,2). Calcium antagonists are a new class of antihyper­
tensive drugs which cause a decrease in vascular smooth muscle tone by lowe­
ring intracellular free calcium levels. Experimentally, they block calcium 
entry into vascular smooth muscle cells, but other mechanisms, such as an in­
terference with calmodulin dependent cellular kinase systems (3), or a stimu­
lation of calcium extrusion mechanisms (4) may also play a role. 
Dihydropyndine calcium antagonists such as nifedipine and felodipine are po­
tent peripheral vasodilators. They lack clinically significant negative ef­
fects on the heart that are prominent with the structurally unrelated calcium 
antagonists verapamil and diltiazem. In studies in vitro, the molar ratio of 
activity of the drug on vascular smooth muscle and the heart is much higher 
for felodipine than for nifedipine (5). Another disadvantage of nifedipine 
is its inactivation by exposure to daylight, making intravenous administra­
tion and the sampling of blood for the determination of plasma concentrations 
cumbersome procedures. Furthermore, nifedipine has a relatively short dura­
tion of action (elimination Τ 1/2 of 1.7 h (6) vs 2.4 h or more for felodipi­
ne (7)). 
Recently, we have reported strong antihypertensive effects of felodipine in 
the treatment of acute hypertension (9). Favourable antihypertensive effects 
have also been described in the chronic treatment of severe hypertension (9), 
where felodipine may be as effective as the potent arteriolar vasodilator mi­
noxidil (10). As described for other dihydropyndines, felodipine has a diu­
retic and natriuretic action (11), which may have a diuretic sparing effect 
in chronic antihypertensive treatment. Several authors have reported that a 
reflex stimulation of heart rate seen at the initiation of dihydropyndine 
treatment became less evident when therapy was continued for longer periods 
(12,13), thus making antihypertensive treatment with felodipine monotherapy, 
without the addition of a beta-blocker, an attractive possibility. 
We have treated 27 patients who had moderate to severe hypertension (in 19 
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with some degree of renal insuffiency), with felodipine for a period of up to 
48 weeks. In this paper, we report on the clinical effectiveness and the ef-
fects of the drug on several biochemical parameters. As felodipine interferes 
with calcium homeostasis of vascular smooth muscle cells, we paid special at-
tention to plasma indicators of calcium metabolism. 
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PATIENTS AND METHODS 
We studied 27 patients with moderate (n=10) or severe (n=17) hypertension, 
according to the Julius/Hansson clinical classification (14). Twenty patients 
had been refractory to multiple drug therapy including at least one of the 
following vasodilators: Captopril (n=14), nifedipine (n=13), hydralazine 
(n=2), minoxidil (n=2)F or diazoxide (n=1). Supine pretreatment blood pres-
sure was 202/126 ± 29/17 mmHg (mean ± SD). In nine patients where felodipine 
therapy was instituted for the management of an acute hypertensive episode, 
pretreatment blood pressure was defined as the mean value of 10 consecutive 
readings at 2 m m intervals, measured with an automatic recorder (Artenoson-
de 1225) after 45 min supine rest. In the remaining 18 patients it was defin-
ed as the mean of duplicate readings at three subsequent outpatient visits on 
previous treatment (sphygmomanometry, Erkameter 300). Other relevant clinical 
data are given in Table I. In 10 patients all previous antihypertensive medi-
cation could be stopped 3 weeks before felodipine was started. Fifteen of the 
remaining 17 patients used a vasodilator which was discontinued in the last 
48 h before the first dose of felodipine was given. The patients who used a 
diuretic (n=12) and/or a beta-blocker (n=14) continued taking these drugs 
when felodipine was started. 
The study was performed as an open, prospective phase II feasibility study, 
during which the patients were followed at 6-week intervals for 24 weeks. 
Twenty-one patients continued taking felodipine after 24 weeks, and 19 pa-
tients completed a 48-week follow-up. 
Table I. Clinical data of 27 hypertensive patients 
Mean age (years)* 
Sex (male/female) 
Origin of hypertension 
Essential 
Renal 
Renovascular 
Left ventricular hypertrophy** 
Retinopathy*** 
Grade 0 
Grade I-11 
Grade III-IV 
Known duration of hypertension (months)* 
Endogenous creatinine clearance (ml/min/1.73m ) 
more than 70 
30-70 
less than 30 
* mean ± SD, range in parentheses 
** ECG-cnteria according to Romhilt and Estes (15) 
*** according to criteria of Keith, Wegener and Barker (16) 
43.2 ± 15.9 (17-69) 
14/13 
10 
16 
1 
17 
1 
16 
10 
70.3 ± 76.2 (0-288) 
8 
9 
10 
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Blood pressures (Erkameter 300, means of two measurements) and heart rates 
were taken after 5 min supine rest and after one m m of standing with routine 
sphygmomanometry at 3.9 ± 1.4 h after intake of the last tablet. 
Felodipine was given in 5 and 10 mg tablets three to four times per day, as 
preliminary experiments in 17 hypertensive patients in our clinic showed some 
loss in blood pressure control 12 h after tablet intake (Δ mean arterial 
pressure after 12 h: -16.4 + 14.2SÍ compared with -28.3 + 14.0%, two h after 
tablet intake, mean ± SD, n=27, p<0.0001). Felodipine was started in a dose 
of 15 mg daily, which was increased to a maximum of three times 20 mg per 
day. We tried to restrict the use of diuretics and beta-blockers. Thus a diu-
retic (chlorthalidone when endogenous creatinine clearance (ECC) was higher 
than 30 ml/min/1.73m , or furosemide when it was lower) was added only when 
clinically significant oedema was noted, and a beta-blocker only when supine 
heart rate was above Θ0 beats per min on several occasions, or when the pa­
tients complained of palpitations. Except for the choice of a diuretic, pa­
tients with renal failure were treated in the same way as those with normal 
renal function. 
At each visit body weight was measured, the presence of ankle oedema was not­
ed, spontaneously reported side effects were recorded, and blood samples were 
taken for the determination of laboratory parameters, including plasma ioniz­
ed calcium levels corrected for pH (Ionized Calciuii Analyzer, Radiometer, Co­
penhagen). Blood samples for the determination of felodipine plasma levels 
(17) were taken in 24 patients at 82 visits. Mean arterial pressure (MAP) was 
calculated as the diastolic blood pressure plus one third of the pulse pres­
sure. Patients were classified as non-responders when the decrease in supine 
MAP was less than 10S on at least 50% of follow-up visits. 
Statistical comparisons were made with Student's t-test or with Wilcoxon's 
rank-sum test for paired observations. Correlations were calculated according 
to Spearman. Results were considered significant when p-values were below 
0.05. Unless indicated otherwise, all data are given as means ± SD. 
The study protocol was approved by the Ethical Committee of the Sint Radboud 
Hospital, Nijmegen. All patients gave written informed consent to participate 
in the study. 
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RESULTS 
Of the 27 patients included in the study, 23 completed a 24-week, and 19 a 
48-week follow-up. No patient had to withdraw for drug-related reasons. One 
patient was lost from follow-up when she moved to another region. Two pa­
tients stopped taking felodipine at the initiation of maintenance dialysis 
treatment, and one at the start of the treatment of a rejection episode of 
his kidney transplant. 
Table II gives the number of patients included in each follow-up visit, the 
mean dose of felodipine they used, as well as the extent to which diuretics 
or beta-blockers were concomitantly used. Of the 27 patients studied, 11 
needed a daily dose of felodipine above 30 mg, 13 a dose from 20 to 30 mg and 
only three could be managed with a dose below 20 mg throughout the study. 
Table II. Patient data at follow-up 
Week: б 12 1Θ 24 J6 4Θ 
Nunber оГ p a t i e n t s 27 26 24 23 21 19 
Ооэе o f Telodlpine (mg/24h)a 
Other ant ihypertensive drugs b 
- none (%) 
- d i u r e t i c only (S) 
- betablocker only (%) 
- d i u r e t i c and 
betablockar (SO 
Decrease in supine MAP (%)a 
2В.6ІІ4.Э 
J7.0 
_ 25.9 
37.Q 
-23.а±із.і 
29 
-24. 
.4±15. 
34.6 
3.8 
19.2 
42.3 
. » i l l . 
.8 
0 
31 
-24 
.9±15. 
16.7 
8.3 
37.5 
37.5 
.7±11. 
9 
7 
31 
-25 
.5*16. 
17.4 
4.4 
43.5 
34.7 
.oto. 
7 
5 
32 
-26, 
. З І І 2 . 7 
4.θ 
9.5 
57.1 
28.6 
,0t12.4 
30 
-27 
.7 І ІЭ.1 
5.3 
10.5 
52.6 
31.6 
.7±16.1 
a: meana ± SO 
b: % of pat ients included at fol low-up v i s i t 
Figure 1 shows that blood pressure was effectively lowered throughout fol­
low-up. Standing systolic blood pressures were slightly lower than supine, 
both before and during felodipine treatment (p<0.05), while standing diasto­
lic blood pressures did not differ from supine values. No orthostatic hypo­
tension was observed. Mean supine MAP remained at 25% below pretreatment le­
vels at each visit (Table II). Only four patients could be classified as 
non-responders. In three of them this appeared to be due to poor patient com­
pliance (no decrease in blood pressure and undetectable plasma levels of fe­
lodipine in spite of adequate dosing of felodipine, and a satisfactory res­
ponse O20SÓ decrease of supine MAP to the same dose of felodipine on other 
occasions when plasma levels were in the therapeutic range). In the fourth 
patient, with severe angina pectoris and intermittent claudication, it was 
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Figure 1. Effects of felodipine on blood pressure and heart rate in supine 
(first column, closed symbols) and standing (second column, open 
symbols) positions in 27 patients with moderate to severe 
hypertension (means + SEM). 
thought dangerous to lower blood pressure further. 
Mean individual plasma levels of felodipine were 12.3 ± 7.2 nmol/1. In 18 pa­
tients (.75%) mean plasma levels within the therapeutic range of 5-20 nmol/1 
were found, in three patients they were higher than 20 nmol/1. We found a 
significant correlation between individual mean log plasma levels of felodi­
pine and the mean percentual change in supine MAP (r=-0.52, p<0.01, n=24). 
Table III shows that no differences were found between groups of patients 
with different levels of renal function with respect to the dose, plasma le­
vels, and antihypertensive effects of felodipine. Clinically significant oe-
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Table III. Antihypertensive effect of chronic treatment with felodipine at 
different levels of renal function3 
Endogenous creatinine clearance (ml/min/1.73m ) 
Number of patients > 70 3 0 - 7 0 < 30 
Mean dose of felodipine 27.1+3.8 36.1±3.7 27.0±5.3 
(mg/24 h ) b 
Plasma felodipine 10.7±2.1 14.9±3.0 10.8±2.1 
(nmol/l)b 
Δ Supine MAP (S) b -27.2±4.6 -25.8±4.4 -23.8+2.2 
a: means + SEM 
b: individual means have been pooled 
dema, present in 4 patients before felodipine, developed in 13 patients in 
the course of the study. All these patients had some form of renal dysfunc­
tion. The occurrence of oedema necessitated the institution of diuretic the­
rapy in 4 patients or an increase in the dose of furosemide in 8 other pa­
tients. This led to relief of oedema, but had no influence on the level of 
blood pressure. Oedema was never reason for withdrawal of felodipine thera­
py. Patients with an ECC above 70 ml/min/1.73 m 2 needed a diuretic in 25% of 
cases, those with lower clearances in 505«. 
Thirteen patients were not using beta-blockers at the start of felodipine 
treatment. In eight of them (pretreatment heart rate 89±11 beats/min) a be­
ta-blocker (metoprolol 2 χ 50 mg in four patients, atenolol 1 χ 100 mg in 
three patients, and propranolol 3 χ 40 mg in one patient) had to be added be­
cause of a high pulse rate (n=3) or complaints of palpitations (n=5) after 
one to 24 weeks (mean 11.4 weeks). After the addition of the beta-blocker the 
supine heart rate decreased from 101+14 to 68+5 beats per min (p<0.001), and 
palpitations disappeared in all five patients. Addition of a beta-blocker did 
not lead to a further decrease in supine MAP (-21.3±13.5Ä before and -20.9+-
19.8Й after). 
Other side effects reported during antihypertensive treatment with felodipine 
consisted of complaints of headaches (n=4), orthostatic dizziness (n=4), a 
temporary increase in symptoms of angina pectoris (n=3) or intermittent clau-
dicatio (n=3), muscle cramps (n=3) or dyspepsia (n=3). In 19 instances 
(82.75») these side effects were reported while felodipine was taken in combi­
nation with a beta-blocker. Seven patients complained of tiredness during 
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felodipine therapy, six of them also used a beta-blocker. In three of these 
patients the dose of felodipine could be lowered, which resulted in disap­
pearance of this complaint. 
Table IV. Laboratory parameters before and during felodipine therapy* 
WEEK 0 6 12 18 2& 16 48 
Number of p a t i e n t s 
at fo l low-up v i s i t 27 27 26 24 23 21 19 
Creat in ine 296*316 299*335 291*310 276*·324 296*320 299±352 317*378 
(μιηοΙ/Ι) 
Total c a l c i u n 2.28*0.15 2.36*0.15° 2.34*0.18 2.39*0.11° 2.34*0.14 2.40*O.11b 2.42±0.12B 
(mmol/1) 
Ionized c a l c i u n 1.16*0.08 1.24i0.08 c 1.20*0.D9b 1.21*0.06 c 1.21*0.07b 1.22*0.08b 1.20±0.0Ba 
(mmol/l) 
Phosphate 1.20*0.35 1.31±0.34 1.33*0.57 1.17*0.29 1.20*0.32 1.25±0.28 1.15+0.31 
(mmol/l) 
Alka l ine phosphatase a i i 2 3 85*36 76*20 77*21 7β±27 80*34 80+24 
(O/I) 
Une acid 0.35+0.11 0.Э6+0.1Э 0.36+0.11 0.35*0.11 0.36+0.12 0.42+0.14a 0.40+0.12 
(mmol/l) 
* plasma leve ls given as means ± 50 
a: p<0.05 Ь: p<0.01 c: p<0.001 (paired t - t e s t j 
Table IV gives the outcomes of laboratory variables, measured before and du­
ring felodipine therapy. Plasma levels of creatinine, sodium, ALAT, ASAT, 
LDH, uric acid, and alkaline phosphatase did not change. Haemoglobin and 
haematocnt remained stable. Plasma total and ionized calcium levels rose 
significantly. Plasma levels of phosphate did not change when all patients 
were analyzed together, but when only patients with an ECC above 30 
ml/min/1.73m2 were evaluated, an increase in plasma phosphate levels was seen 
during felodipine therapy, parallelling rises in ionized calcium levels 
(Figure 2). Indeed, a significant correlation was found between the 
individual means of the changes in plasma phosphate and those in ionized 
calcium (r=0.75B; ρ<0.0ΰ1, n=14). We could not find a relation between a 
change in prescription of thiazide diuretics and the rise of plasma ionized 
calcium levels. In individual cases, there was no significant correlation 
between the decrease in systolic or diastolic blood pressures and the change 
in plasma ionized calcium. 
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Figure 2. Effects of chronic antihypertensive treatment with felodipine on 
plasma ionized calcium (ION Ca^-··), and phosphate (PO4) in 17 pa-
tients with moderate to severe hypertension and an endogenous 
creatinine clearance above 30 ml/min/1.73m2. 
(Means ± SEM. * p<0.05, ** p<0.01, *** p<0.001, compared to base-
line levels (week 0)). 
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DISCUSSION 
Our study clearly shows the efficacy of the calcium antagonist felodipine in 
the chronic treatment of moderate and severe hypertension. Because of the 
high pretreatment levels of blood pressure, and of the hazards imposed on the 
large proportion of patients with impaired renal function when such a high 
blood pressure is not treated adequately (1B), a placebo control period was 
not included. Antihypertensive therapy with felodipine led to a sustained lo­
wering of both systolic and diastolic blood pressures of about 25% over a pe­
riod of 24 to 48 weeks. In none of the 27 patients studied, hypertension 
could be regarded as truly resistant to the drug. No differences in antihy­
pertensive effects of felodipine, or in the mean dose of the drug needed to 
control blood pressure, were found between patients with renal failure and 
those with normal renal function. The antihypertensive effects of felodipine 
show a certain dose-dependency (11). Accordingly, the mean dose of felodipine 
needed in our study to control blood pressure, (31.5 + 16.7 mg/24 h after 24 
weeks), was higher than in other studies where the drug was given to patients 
with less severe hypertension (9). The correlation of the antihypertensive 
effect of felodipine with log plasma levels of the drug suggests that an in­
crease in the dose of felodipine may lead to a further reduction in blood 
pressure in patients not controlled on a low dose of the drug. 
Side effects of antihypertensive therapy with felodipine were frequent, but, 
apart from oedema formation, palpitations, and to a certain extent tiredness, 
cannot be ascribed with certainty to the investigational drug, since a beta-
blocker was used in most cases together with felodipine. The side effects we 
observed in our study were never severe enough to stop felodipine treatment. 
Antihypertensive treatment with vasodilators is generally associated with 
compensatory renal sodium and water retention leading to oedema formation 
(19,20). Clinically significant oedema formation was seen in 13 patients 
(4 Й) in our study. Oedema formation was relieved by the prescription of a 
diuretic or by increasing the dose of an already prescribed diuretic. Not un­
expectedly, our results suggest that oedema was more frequent in patients 
with renal dysfunction. Yet, in spite of the difficult category of patients 
treated in the present study, only 50% of patients with an ECC below 70 
ml/min/1.73 m^ needed a diuretic to combat renal fluid retention, and in 
only 25% of those with an ECC above 70 ml/min/1.73 aß a diuretic was 
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prescribed because of oedema. It remains to be settled whether the relatively 
low need of diuretics in comparison with other vasodilators relates to the 
natriuretic effect of felodipine, which was shown in acute studies in normo-
tensive volunteers (21), and in patients with hypertension (11). In eight of 
our patients a beta-blocker had to be added to felodipine in order to di-
minish a too strong reflex cardiostimulation which had led to a sustained in-
crease in heart rate and complaints of palpitations. Thus, in these patients 
with moderate to severe hypertension, we could not confirm the findings of 
Hallbáck-Nordlander and Thalén in animals (12) and of Kleinbloesem et al in 
hypertensive patients (22), that an initial increase in heart rate disappears 
on chronic treatment with dihydropvndine calcium antagonists. 
There was no deterioration of renal function immediately after the start of 
felodipine treatment. The long-term influence of the drug on renal function 
was more difficult to assess, especially in four patients with progressive, 
near end-stage, renal disease. However, in the remaining group there was no 
deterioration of renal function after prolonged felodipine therapy (Table 
IV). Since slight uricosuric effects of dihydropyndines have been described 
when they are administered acutely (21,23), plasma urate levels were monitor-
ed in this study. However, no change in plasma urate levels was found. 
A curious finding in our study is the rise in plasma ionized calcium levels. 
This rise in ionized calcium levels was not related to the change in blood 
pressure or to the initiation of thiazide diuretics. We did not find a change 
in plasma alkaline phosphatase levels. This may argue against a mobilization 
of calcium from bone. Resnick et al (24) reported a similar trend in low re-
nin essential hypertensives treated with nifedipine. Plasma phosphate levels 
did not appear to change when data from all patients were analyzed together. 
In patients with moderate to severe renal insufficiency, plasma phosphate le-
vels are difficult to interpret because confounding factors come into play, 
such as decreased renal excretion on the one hand, and measures to decrease 
intestinal absorption (protein restriction, phosphate binding agents) on the 
other hand. When for this reason, patients with an ECC below 30 ml/min/1.73m2 
were excluded from analysis we were surprised to find a parallel increase in 
plasma phosphate levels and ionized calcium levels. These changes have to be 
confirmed in other studies. 
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In conclusion, our long-term results in an open prospective trial of felodi-
pine in patients with moderate to severe hypertension show that felodipine is 
an effective antihypertensive drug. Felodipine was given in combination with 
a betablocker or a diuretic in BOS and in 40% of cases, respectively. Side 
effects were frequent, but generally of minor clinical importance. Chronic 
antihypertensive treatment with felodipine appeared to have no deleterious 
effect on renal function, as judged by plasma creatinine levels. The diuretic 
sparing effect of felodipine may be an advantage. Our finding of an increase 
in plasma ionized calcium levels is not readily explained, and needs further 
confirmation. 
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Summary hilodipim and plaiebo nere inhmd in a double blind irosuner stud\ in 10 hcallh\ 
normoumi\Ì \olunhen Compared η uh plaiebo felodipim caused a цпіГісапі decrease 
in diaslolii blood pressure and forearm \акчІаг rcsManie while there nas no ihangi in 
MSÍO/ÍI blood premire The mcv in heart rate plasma renin aclnih and plasma nor 
adnnahm (norepinephrine) concentration further demonstrated the \asodilating actnitv 
of felodipine Plasma aldosterone adrenaline {epinephrine) and antidiuretic hormone con-
tentianons were similar after a 90 minute infusion of felodipine or placebo The response 
of plasma aldosterone levels to exogenous adcnoiorlicotrophic hormone showed e\idence 
oí a slicht blunting during felodipine infusion Felodipine had a marked diuretic effect 
probabh seiondan to an imreasc in nalriurests which mi^hl be due to a direct tubular 
effect of ihi drug 
Felodipine is a powerful new antihypertensive 
drug belonging to the dihydropyndine class of cal-
cium antagonists These drugs lower peripheral re-
sistance by interference with the intracellular free 
calcium level of vascular smooth muscle cells, and 
have been used successfully in the treatment of 
hypertensive patients (Elmfcldt and Hedner 1983, 
Lederballe Pedersen and Mikkelsen, 1978, Olivan 
et al 1979) 
Although acting primarily as direct arteriolar 
vasodilators, they appear to cause relatively little 
sodium retention Nifedipine is structurally closely 
related to felodipine and probably has a diuretic 
effect (Chnstcnscn et a l , 1982, Klutsch et a l , 1972, 
Marre et al 1982) This diuretic effect could con-
tribute to the short term antihypertensive effects 
of the drug and may be responsible for the fact 
that oedema formation during long term therapy 
seems to be comparatively rare (Lederballe Ped-
ersen and Mikkelsen, 1978, Olivan et a l , 1979) 
Calcium antagonists attenuate the release of al-
dosterone by isolated adrenal glomcrulosa cells in 
\itro (Fakunding and Call, 1980, Schiffnn el a l , 
1981) and several studies have reported the lack 
of a nsc in plasma aldosterone levels in spite of an 
increase in plasma renin activity when nifedipine 
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was given as short term therapy to hypertensive 
patients (Hiramatsu et al., 1982, Huysmans et a l , 
1983). In normotensive volunteers, the short term 
rise in plasma aldosterone levels caused by angio­
tensin Π infusion can be attenuated by the admin­
istration of a single dose of nifedipine (Millar et 
al.. 1983) 
Therefore, we evaluated the hormonal and di­
uretic properties of felodipine, together with its 
haemodynamic effects, in 10 normotensive volun­
teers. We also tested the influence of felodipine on 
the nse in plasma aldosterone levels caused by ex­
ogenous adenocorticotrophic hormone (ACTH). As 
the short term antihypertensive effects of a calcium 
antagonist appear to be related to pretreatment 
blood pressure (Andersson el al., 1984, MacGregor 
et al., 1982), we did not expect a major fall in blood 
pressure in our normotensive volunteers. This en­
abled us to study the possible direct diuretic action 
of felodipine without the interference of a major 
fall in systemic blood pressure. 
1. Methods and Materials 
1 1 Subjects 
Ten healthy male volunteers aged 26 to 40 years 
(mean age 32) participated in the study. All had a 
normal mean bodyweight (72 5 ± 7.9kg, mean ± 
SD), height (1796 ± 4.8cm), and blood pressure 
(119/76 ± l l/5mmHg) as measured by routine 
sphygmomanometry (Erkameter 300). The sub­
jects did not take any drugs and had not smoked 
or drunk alcoholic beverages for at least 12 hours. 
They were advised to continue with their usual diet, 
avoiding excessive intake of salt. After a light 
breakfast at 7am no food or dnnk was given during 
the experiments, which were performed between 
8am and noon. 
1 2 Study Protocol 
After 1 hour of supine rest, felodipine or pla­
cebo was infused for 150 minutes in a double-blind 
manner on 2 study mornings with an interval of 
at least 1 week. Felodipine was infused as a solu­
tion containing 0.05 mg/ml of the drug in solvent 
al a constant rale of 0 01 mg/min The solvent ve­
hicle was infused on placebo days. 1-24 ACTH 
250Mg was given as an intravenous bolus after 90 
minutes infusion Unne was sampled before and 
after the expenmenls. 
I 3 Assessments 
During the expenments, supine blood pressure 
was measured every 2 minutes (Artenosonde 1225) 
and heart rale was calculated from a simultane­
ously recorded ECG strip. Forearm blood flow 
measurements were made by mercury strain-gauge 
plethysmography of the nghl forearm (mean of 5 
readings every 15 minutes) using a pulse cuff to 
exclude the circulation of the hand. 60 minutes be­
fore the start of the infusion, 2 intravenous can-
nulae were inserted in an anlecubital and an an­
tebrachial vein of the left arm, the first for the 
infusion of felodipine or placebo, the other for the 
sampling of blood Both cannulae were kept open 
by infusion of isotonic saline Blood samples for 
the determination of felodipine concentrations were 
taken at 30-minute intervals Felodipine plasma 
concentrations were measured by gas chromato­
graphy with electron-capture detection (Ahnoff, to 
be published) 
Plasma renin activity (Drayer and Benraad, 
1975) and plasma levels of aldosterone and Cortisol 
(De Man et al.. 1980) were measured at -20, 0, 30, 
60 and 90 minutes of infusion of felodipine or pla­
cebo, and 20, 30 and 60 minutes after injection of 
ACTH. Blood samples for the determination of 
plasma adrenaline (epinephrine), noradrenaline 
(norepinephrine) and antidiuretic hormone (ADH) 
were taken at -20, 0, 90 and 150 minutes. Plasma 
catecholamine levels were determined by a radio-
enzymatic assay (Hoffman et al., 1982) and ADH 
by a radioimmunoassay (Vasopressin-RIA kit, 
Buhlmann Lab Ltd, Basel, Switzerland). 
Routine analytical methods were used for the 
determination of plasma Na+, ΚΛ CI", total and 
ionised Ca2*, Ρ Ο / " , urea, creatinine, urate, 
haemoglobin, haemalocrit, total protein and al­
bumin levels, plasma and unne osmolality (blood 
levels measured at 0, 90 and 150 minutes) and 
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urinar> pH Only the urine sampled at the end of 
the experiment was analysed A total amount of 
220ml of venous blood was drawn during each ex­
periment, and was replaced by isotonic saline 
The study protocol was approved by the Ethical 
Committee of the Sint Radboud University Hos­
pital, Nijmegen The subjects gave their informed 
consent after a full explanation of the nature of the 
study protocol 
1 4 Calculations and Statistical Analysis 
The means of 5 consecutive readings were taken 
to represent the blood pressure and heart rale at 
15-minule intervals and were used for analysis 
Mean arterial pressure was calculated as the dia­
stolic blood pressure plus one-third of the pulse 
pressure, and forearm vascular resistance as mean 
arterial pressure divided by forearm blood flow 
The mean value of all 3 measured plasma con­
centrations of a substance was used for the calcu­
lation of its renal clearance Free water clearance 
was calculated as unnary flow (ml/min) minus os-
molal clearance, fractional excretion rate of a sub­
stance as renal clearance of the substance/endo­
genous creatinine clearance X 100% Relative 
changes (%) in the study parameters were calcu­
lated using the mean values at -20 and 0 minutes 
as basal for the effects of felodipine, and using the 
90-minule value as basal for the effects of ACTH 
Statistical compansons between paired obser­
vations were made with Student's t-test, if normal 
distribution applied, or with Wilcoxon's rank-sum 
test Compansons between curves were made with 
a disinbution-free analysis of vanance (Koztol et 
al, 1981) In this analysis of vanance, the results 
of felodipine and placebo administrations are con­
sidered to be denved from 2 independent samples 
instead of 1, therefore this analysis tends to un­
derestimate effects not occurring by chance Cor­
relations were calculated according to the Spear­
man rank correlation method A ρ level of 0 05 or 
less was considered to be the level of statistical sig­
nificance All values given in tables and text are 
expressed as means ± SD. 
2. Results 
2 1 Haemodynamics 
Baseline variables were similar on both study 
days (table I) Compared with placebo, felodipine 
infusion induced lower diastolic blood pressures, 
while not affecting systolic blood pressures Heart 
rate and forearm blood flow increased, whereas 
Table I Haemodynamic effects (mean ± SD) of felodipine m 10 normotensive volunteers 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Mean arterial pressure (mm Hg) 
Heart rate (beats/mm) 
Forearm blood flow (ml/mln/100ml) 
Forearm vascular resistance (U) 
Baseline values' 
felodipine 
106 ± 7 
70 ± 8 
83 + 7 
63 ± 7 
2 0 + 1 0 
49 + 17 
placebo 
106 ± 6 
70 ± 5 
63 ± 5 
61 ± 6 
2 2 + 1 0 
45 ± 14 
Relative changes (%) 
after 90 minute infusion15 
felodipine 
+ 1 2 ± 3 4 
- 2 9 ± 6 1 
- 1 3 ± 4 0 
+14 2 ± 7 0 
+30 0 ± 35 7 
-20 7 ± 16 5 
placebo 
+0 9 ± 
+7 0 ± 
+4 3 ± 
- 3 6 ± 
- 1 4 0 + 
+27 2 ± 
4 3 
6 6 
4 7 
6 5 
25 7 
341 
Significance' 
NS 
p < 001 
ρ < 001 
p < 001 
p < 005 
p < 0 0 5 
a After 60 minutes supine rest No significant differences (t-test) existed between felodipine and placebo 
b Compared with baseline values 
с Levels of significance given by comparison of curves (of relative changes) from 0 to 90 minutes infusion by analysis of variance 
(Koziol el al 1961) [NS - not significant] 
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Fig. 1. Relative changes (mean ± SEM) m systolic and diastolic blood pressure (BP), heart rate (HR) and forearm vacular resistance 
(FVR) caused by felodipme ( · · ) or placebo (O O) in 10 normotensive volunteers. * ρ < 0 05. " ρ < 0 01, NS = not significant 
(analysis of variance) 
forearm vascular resistance decreased when felo-
dipine was infused (table I; fig. 1). The maximal 
percentage decrease in diastolic blood pressure was 
more when the pretreatment diastolic blood pres­
sure was higher (r = -0.70; ρ < 0.05). 
2.2 Hormonal and Biochemical Effects 
of Felodipine 
cantly on felodipine, but not on placebo, whereas 
the rises in plasma adrenaline concentrations were 
the same on both occasions and there were only 
marginal changes in ADH levels. 
Felodipine caused no changes in plasma levels 
of sodium, potassium and ionised calcium, but 
haemoglobin, haematocrit, total protein and al­
bumin concentrations rose significantly (table II). 
Felodipine induced higher plasma renin activity 
levels than placebo, while plasma aldosterone con­
centrations were not affected (table II; fig. 2). 
Plasma noradrenaline concentrations rose signifi-
2.3 Effects of ACTH 
Felodipine had no influence on the rise in sys­
tolic and diastolic blood pressure and heart rate 
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"* Table II Hormonal and biochemical effects (mean ± SD) of felodipine in 10 normotensive volunteers 
Plasma renin activity (ng/ml/h) 
Aldosterone (ng/IOOml) 
Cortisol ing/IOOml) 
Adrenaline (nmol/L) 
Noradrenaline (nmol/L) 
Antidiuretic hormone (pg/ml) 
Osmolality (mosm/kg) 
Na* (mmol/L) 
K* (mmol/L) 
Creatinine (umol/L) 
Haemoglobin (mmol/L) 
Haematocnt ("«) 
Total protein (g/L) 
Albumin (g/L) 
Baseline values» 
felodipine 
13 ± 
7 8 ± 
0 28 < 
017 + 
0 78 ± 
6 7 ± 
283 ± 
142 ± 
3 7 -
80 ± 
8 4 ± 
40 » 
61 + 
40 + 
0 8 
3 2 
0 08 
0 08 
0 24 
1 7 
6 
1 
02 
7 
0 5 
2 
3 
2 
pla-ebo 
1 0 
5 3 
0 26 
018 
0 90 
7 5 
294 
142 
3 8 
78 
8 2 
39 
61 
39 
± 0 6 
± 4 2 
± 0 08 
± 0 1 2 
± 041 
± 3 0 
± 5 
± 2 
± 0 3 
^ 8 
+ 0 7 
± 3 
± 3 
± 1 
Relative changes(%) 
after 90 minute 
felodipine 
+ 3 1 3 ± 
-26 1 ± 
-26 8 ± 
+50 5 ± 
+71 7 ± 
+ 1 1 ± 
+0 3 + 
- 1 0 ± 
+ 1 0 ± 
- 7 7 · 
+5 3 + 
+6 2 ± 
+8 3 ± 
+5 4 ± 
65 2 
32 9 
30 4 
45 7 
30 8 
179 
0 7 
0 9 
5 0 
6 1 
3 1 
2 9 
4 7 
4 3 
infusionb 
placebo 
-24 9 
+5 6 
- 1 0 8 
+55 3 
+ 183 
+ 132 
- 0 2 
- 0 7 
+2 4 
- 4 1 
+0 7 
+0 8 
+2 9 
+0 0 
τ 
± 
± 
± 
± 
± 
± 
± 
+ 
+ 
± 
± 
+ 
+ 
24 0 
81 7 
48 9 
60 4 
138 
68 2 
1 1 
1 4 
5 0 
109 
1 2 
3 0 
3 0 
2 9 
Significance0 
ρ < 002 
NS 
NS 
NS 
ρ < 001 
NS 
NS 
NS 
NS 
NS 
p < 0 0 5 
ρ < 0 0 5 
p < 001 
ρ < 001 
After 60 minutes supine rest No significant differences (Wilcoxon s test) existed between telodipme and placebo 
Compared wth baseline values 
Levels of significance given by comparisons of curves (of relative changes) from 0 to 90 minutes infusion by analysis of variance 
(Koziol et al 1981) [NS = not significant] 
caused by injection of ACTH (table III). However, 
the relative changes in forearm blood flow and 
forearm vascular resistance during the 60 minutes 
after ACTH injection were significantly different 
(p < 0 05), forearm blood flow increasing and fore­
arm vascular resistance decreasing on felodipine 
(tabic III). 
Before injection of ACTH, plasma aldosterone 
and Cortisol levels were similar on felodipine and 
placebo, while plasma renin activity values were 
significantly higher after a 90-minute infusion of 
felodipine (14 ± 0.7 vs 0 7 ± 0 4 ng/ml/h on pla­
cebo, ρ < 0 05). ACTH did not cause significant 
changes in plasma renin activity, while plasma Cor­
tisol levels increased by 200% during both felodi­
pine and placebo administration (fig. 2). The dif­
ference in the aldosterone response curves just 
failed to reach statistical significance (analysis of 
vanance; ρ = 0 10), although the percentage in­
crease in plasma aldosterone levels was higher in 
the placebo expenmenls 20 and 60 minutes after 
ACTH (p < 0 05, Wilcoxon's rank-sum test). 
2 4 Renal Effects of Felodipine 
Felodipine caused an increase in unnary flow 
and in natnuresis, while there was no change in 
endogenous creatinine clearance compared with 
placebo (table IV). Fractional excretion rates of 
sodium and chloride doubled on felodipine and 
there was some increase m the fractional excretion 
rate of urea and urate Dunng both treatments there 
was a similar net retention of water (negative free 
water clearance) [table IV]. 
2 5 Side Effects 
Minor side effects dunng felodipine therapy were 
common. Slight headache dunng or immediately 
after the infusion occurred in 9 subjects, facial 
flushing in 10 subjects and a sensation of a full 
urinary bladder in 3 Three subjects expenenced 
orthostatic dizziness after the infusion of felodi­
pine, and one other had the same complaint after 
placebo. 
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2 6 Felodipine Plasma Concentrations 
Fig. 2. Hormonal changes (mean ± SEM) caused by intraven­
ous felodipine ( · · ) or placebo (O O) in 10 normoten-
sive volunteers After 90 minutes of infusion, a bolus injection 
of 250μς 1-24 ACTH was given intravenously. " ρ < 0 01, NS 
= not significant (analysis of variance). 
Felodipine plasma concentrations were within 
the range of 5 to 20 nmol/L, considered to be the 
therapeutic range in hypertensive subjects (Elm-
feldl and Hedner, 1983; Leonelti el al., 1984), from 
30 minutes after the start of the infusion of felo­
dipine until the end of the experiment. 
3. Discussion 
In this placebo-controlled study in 10 normo-
tensive subjects, felodipine caused no change in 
systolic blood pressure and only a modest decrease 
in diastolic blood pressure in spite of adequate 
plasma concentrations of the drug. We found that 
the maximal effect of felodipine on diastolic blood 
pressure was greater when basal values were higher, 
which agrees with data on the short term effects of 
nifedipine on blood pressure levels in 29 normal 
subjects in the study by MacGregor et al. (1982). 
Although the influence of felodipine on blood pres­
sure was small, forearm vascular resistance de­
creased clearly. This decrease was accompanied by 
rises in heart rate, plasma renin activity and plasma 
noradrenaline levels, probably as a consequence of 
baroreceptor-mediated compensatory reactions to 
arteriolar vasodilation (Koch-Wescr, 1974). These 
haemodynamic and hormonal changes, and also the 
observed side effects dunng felodipine infusion, 
agree with a primary vasodilatory action of the 
drug. 
In another study using the same intravenous 
dose of felodipine, we found stronger blood pres-
sure-lowenng effects in hypertensive patients (Slui­
ter et al., 1985). This could be due lo a difference 
in magnitude or efficacy of compensatory reactions 
to arteriolar vasodilation. However, the greater ef­
fect in hypertensive patients could also be the con­
sequence of structural changes in the blood vessel 
wall, acting as a 'geometric amplifier' (Folkow, 
1982), or of a greater sensitivity of vascular smooth 
muscle cells to the specific actions of calcium ant­
agonists (Lederballe Pedersen et al., 1978). 
There are 2 indications in our study that aldo­
sterone release might be impaired dunng infusion 
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Table III Relative changes (%) in haemodynamics 30 minutes after injection of ACTH compared with levels |ust before ACTH 
administration in 10 normotensive volunteers (mean ± SD) 
Felodipine Significance8 
Systolic blood pressure 
Diastolic blood pressure 
Heart rate 
Forearm blood flow 
Forearm vascular resistance 
+3 5 ± 5 1 
+4 4 ± 5 5 
+0 9 ± 7 3 
+7 7 ± 15 В 
- 1 7 ± 144 
+6 6 ± 4 4 
+7 9 ± 7 8 
+2 9 i 6 5 
- 1 8 ± 188 
12 8 ± 21 5 
NS 
NS 
NS 
p < 0 0 5 
p < 0 0 5 
a Analysis of variance comparing curves from 90 minutes (injection of АСТМ) to 150 minutes after start ol infusion 
of felodipine. Firstly, plasma aldosterone levels did 
not increase during the first 90 minutes of infusion 
of felodipine, while plasma renin activity was 
clearly higher during felodipine. Secondly, the short 
term aldosterone response to intravenous ACTH 
tended to be lower during felodipine infusion than 
during placebo, in spite of a similar increase in 
plasma Cortisol and the absence of an effect 
of felodipine on plasma potassium levels. How­
ever, these results might have been biased since 
sodium intake was not strictly standardised in 
our study. 
Millar et al (1982) could not find a suppression 
by nifedipine of the adrenal aldosterone release in 
response to an intramuscular dose of ACTH in 
normal volunteers and, as in this study, they failed 
to show a diminished pressor response to ACTH 
caused by the calcium antagonist. Taken together, 
Table IV. Renal effects ol felodipine in 10 normotensive volunteers (mean -» SD) 
Felodipine Placebo Significance8 
Urine output (ml) 
Urinary flow (ml/mm) 
Change in bodyweight (kg) 
Urine osmolality (mosm/L) 
Free-water clearance (ml/mm) 
Creatinine clearance (ml/mm) 
Total urinary excretion Na* (mEq) 
Fractional excrer/on rafes 
Na* (%) 
CI" (%) 
К* (%) 
urea (%) 
urate (%) 
Са
г
* (%) 
PO.3 (%) 
Urinary pH 
741 ± 
3 1 ± 
- 1 1 ± 
521 ± 
- 2 1 ± 
148 2 ± 
100 ± 
2 0 ± 
2 5 ± 
184 ± 
48 7 ± 
9 2 ± 
2 8 ± 
125 ± 
7 74 ± 
272 
1 1 
0 4 
166 
0 9 
23 2 
35 
0 2 
0 2 
8 3 
9 2 
1 7 
1 3 
3 9 
085 
337 
1 4 
- 0 7 
708 
- 2 1 
153 9 
48 
0 9 
12 
155 
40 3 
6 9 
2 5 
102 
7 36 
± 
± 
± 
± 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
± 
110 
0 4 
0 2 
239 
0 7 
26 9 
15 
0 1 
0 1 
6 0 
3 6 
2 0 
1 5 
3 2 
0 67 
p < 001 
ρ < 001 
ρ < 0 0 2 
p < 0 0 5 
NS 
NS 
p < 001 
p < 0 01 
ρ < 001 
NS 
p < 0 0 5 
p < 005 
NS 
NS 
NS 
a WilcoKon s rank-sum test 
65 
however, ihe short term effects of felodipine on 
•\CTH-induced aldosterone release do not seem to 
be of major clinical importance In another study 
in 6 normotensive volunteers, Millar et al (1983) 
did find an impaired pressor and aldosterone re-
sponse to graded infusions of angiotensin II after 
short term, but not after long term, administration 
of nifedipine In our study, the low plasma levels 
of aldosterone dunng the first 90 minutes of in-
fusion of felodipine suggest a similar reduction of 
the short term adrenal aldosterone response to en-
dogenous angiotensin II 
We did not find an important change in plasma 
ADH levels during felodipine, which seems to be 
in contrast with the findings of Thibonmer et al 
(1982), who noted an increase in ADH levels after 
short term administration of nifedipine However, 
the haemodynamic changes in their hypertensive 
patients were more pronounced 
The absence of a major decrease in blood pres-
sure dunng felodipine administration in normo-
tensive subjects provided us with an excellent op-
portunity to study any direct diuretic effect of the 
drug without the interference of a decrease in pres-
sure diuresis (Guyton et a l , 1974) Indeed, one of 
the most sinking effects of felodipine in this study 
was an increase in unne flow and natnuresis, which 
more than doubled compared with placebo, and 
resulted in a greater fall in bodyweight The in-
creases in haemoglobin, haematocnt, total protein 
and albumin concentrations might be a conse-
quence of haemoconcentralion and a decrease in 
plasma volume due to this diuretic effect A di-
uretic effect of felodipine was also found in animal 
studies performed by DiBona and Sawin (1984), 
and has been observed in human subjects by Edgar 
et al (1984) 
We saw no change in ADH levels on felodipine 
or placebo, and felodipine did not impair net free 
water reabsorption (negative and similar free water 
clearance on both study days) DiBona and Sawin 
(1984) found an increase in natnuresis in micro-
puncture studies with felodipine in the normoten-
sive rat that was explained by a decrease in distal 
tubular sodium reabsorption The results of our 
study make an impaired release of aldosterone 
caused by calcium antagonists a less likely cause 
of a distal tubular sodium loss in view of the high 
plasma aldosterone levels dunng the latter part of 
the infusions and of the similar aldosterone levels 
before ACTH on both treatments The lack of an 
effect on urinary potassium excretion, and maybe 
to some extent the higher mean urinary pH on fel-
odipine, argue against a functional defect in the re-
sponse of the distal tubule to the action of aldo-
sterone From our data we cannot exclude the 
diuretic action of felodipine due to an effect on 
proximal tubular mechanisms 
Although the increase in fractional excretion 
rates of sodium and chloride would favour a pnm-
ary tubular effect of felodipine, an alternative ex-
planation could be an effect of the drug on renal 
haemodynamics This could lead to an increase in 
renal blood flow and, in the absence of a major 
change in glomerular filtration as suggested by an 
unchanged endogenous creatinine clearance in this 
study, to a decrease in filtration fraction and a 
diminution of distal sodium reabsorption (Marre 
et al , 1982, Osgood et al , 1978) Further studies 
on the magnitude and mechanisms of the diuretic 
effect of felodipine in hypertensive subjects are 
clearly needed, as such an effect might enhance its 
antihypertensive action and could limit the vaso-
dilation-induced sodium retention on long term 
treatment 
In conclusion, in this placebo-controlled study 
in healthy normotensive volunteers, intravenous 
felodipine caused haemodynamic changes compat-
ible with the action of a vasodilator drug, coupled 
with rises in plasma noradrenaline concentrations 
and plasma renin activity, but with only minor 
changes in plasma aldosterone levels The adrenal 
aldosterone release in response to exogenous ACTH 
seems to be slightly impaired on felodipine, in con-
trast to unimpaired rises in plasma Cortisol levels 
and blood pressure after ACTH 
Felodipine appeared to have a distinct diuretic 
and natriuretic effect, most likely related to the 
direct or indirect effect on tubular sodium reab-
sorption However, the exact nature of this diuretic 
effect needs further investigation 
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CHAPTER VII 
HAEMODYNAMIC, HORMONAL, AND RENAL EFFECTS OF INTRAVENOUS FELOOIPINE IN 
MODERATE HYPERTENSION 
H.E. Sluiter, F.Th.M. Huysmans, J.F.M. Wetzeis, and R.A.P. Koene 
Department of Medicine, Division of Nephrology, Sint Radboud Hospital, 
University of Nijmegen, The Netherlands 
SUMMARY 
The dihydropyridine calcium antagonist felodipine was infused intravenously 
at a rate of 0.01 mg/min during 120 min in 16 patients with moderate hyper­
tension (pretreatment blood pressure 176/109 ± 7/3 mmHg, mean t SEM), and a 
varying degree of renal insufficiency (ECC 54.5 ± 9.1 ml/min/l .73m ). Felo­
dipine caused a decrease in blood pressure (-16.6 ± 1.9Я) and forearm vascu­
lar resistance (-66.9 ± 3.6%), while heart rate (+18.2 ± 3.8%), plasma nor­
adrenaline levels (+75.6 + 10.5%), and plasma renin activity (+41.2 + 16.7%) 
increased. Plasma levels of aldosterone did not increase. Nine patients un­
derwent more detailed renal function studies before and during the infusion 
of felodipine. Felodipine caused a rise in urine flow from 6.4 ± 1.7 to 9.8 ± 
2.6 ml/min, and in urinary sodium excretion from 125 ± 24 to 223 + 39 
μΕς/πύη. Fractional excretion of sodium and effective renal plasma flow also 
rose, while glomerular filtration rate and urinary excretion of potassium did 
not change. Our data confirm the vasodilatory and antihypertensive effective­
ness of felodipine. Even in patients with renal insufficiency, felodipine has 
a diuretic and natriuretic effect, in spite of the fall in blood pressure. 
This natriuretic effect may be secondary to a change in renal haemodynamics 
or to a direct tubular effect of the drug. 
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INTRODUCTION 
Many years after the discovery of their cardiac effects (1), calcium antago­
nists, especially those of the dihydropyndine type, are gaining ground as 
antihypertensive drugs (2,3). Calcium antagonists cause a lowering of blood 
pressure through arteriolar vasodilation (4,5). This vasodilation causes a 
reflex cardiac stimulation which compensates for the negative inotropic and 
chronotropic effects that dihydropyndines have on the heart, as known from 
studies in vitro (6). 
In a previous study in healthy normotensive volunteers, where the dihydropy­
ndine felodipine was infused intravenously at a rate of 0.01 mg/min, we were 
able to demonstrate that the haemodynamic and hormonal effects that could be 
expected from an arteriolar vasodilator (7) were accompanied by a distinct 
diuretic and natriuretic effect (Θ). 
In the present study, we infused felodipine at the same rate in 16 patients 
with moderate hypertension of essential and renal origin. As dihydropyndines 
may cause a stronger fall in blood pressure in hypertensive than in normoten­
sive subjects (9) , we paid special attention to quantitative changes in hor­
monal parameters, such as noradrenaline, PRA, and aldosterone levels, brought 
about by the drug. A diuretic effect of felodipine has been described in hy­
pertensive patients also (10). Therefore, we performed more detailed renal 
function studies in nine patients in order to establish whether changes in 
renal haemodynamics accompanied the diuretic effect of the drug. 
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PATIENTS AND METHODS 
Felodipine was infused in 16 patients with moderate hypertension and a pre-
treatment blood pressure of 176/109 + 7/3 mmHg (mean +_ SEM, Artenosonde 
1225, mean of five readings after one h of supine rest). Ten patients (pre-
treatment blood pressure 178/110 ¿ θ/4 mmHg) had not received antihyperten­
sive drugs for three weeks before the infusion of felodipine. Other pertinent 
patient characteristics are given in Table I. Felodipine was infused intrave­
nously at a constant rate of 0.01 mg/min during 120 m m . The total dose of 
felodipine was 0.016 _+ 0.001 mg/kg. During the experiments the patients were 
lying on a bed in a quiet room from one h before until 30 min after the infu­
sion of felodipine. Blood pressures were measured with an automatic recorder 
(Artenosonde 1225) at 2 m m intervals. Heart rate was calculated from a si­
multaneously recorded ECG-stnp. At 15 m m intervals, forearm blood flow 
(FBF) was measured by mercury strain gauge plethysmography using a pulse cuff 
to exclude the circulation of the hand. Blood samples for the determination 
of felodipine plasma levels (14) were taken at 30 m m intervals through a se­
cond indwelling venous cannula. Every 40 m m venous blood was drawn for the 
determination of plasma renin activity (PRA,15), aldosterone, and Cortisol 
(16) levels. Plasma adrenaline, noradrenaline (17), sodium, and potassium le­
vels were measured before felodipine, at the end of felodipine infusion, and 
30 min after the end of the infusion. The mean values of five consecutive 2 
m m interval readings of blood pressure and heart rate were used for analy­
sis. The mean value of five curves was used as one FBF reading. Mean arterial 
pressure (MAP) was calculated as diastolic blood pressure plus one third of 
the pulse pressure. Forearm vascular resistance (FVR) was calculated as 
MAP/FBF, and expressed in arbitrary units. In nine of the patients (mean en­
dogenous creatinine clearance (ECC, 57.2 + 13.9 ml/min/1.73 m^), of whom six 
had not received antihypertensive drugs in the previous three weeks, renal 
Table I. Clinical characteristics of 16 hypertensive patients 
Male/fernal e 11/5 
Age (years)3 45.6 +_ 3.5 
Endogenous creatinine clearance (ECC, ml/min/1.73m2)a 54.5 + 9.1 
ECO70 6 
30<ECC<70 5 
ECC<30 5 
Cause of hypertension 
essential 6 
renal 10 
Seventy of hypertension 
WHO 9 t a g e b I 2 
II 4 
I I I 10 
Fundoscopic changes above grade I e 7 
ECG: l e f t ventr icular hypertrophy d 7 
a: mean ^ SEM 
b: r e f . 11 
c: r e f . 12 
d: r e f . 13 
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clearance studies were performed using intravenous infusion of an isotonic 
solution of 10% inulin (laevofructosan, Inutest") and 2.55S para-aminohippu-
n c acid (PAH). After a bolus infusion at a rate of 0.4 ml/kg in 10 minutes, 
a continuous infusion of the inulin and PAH solution was given at a rate (in 
ml/min) of 0.004 times the previously determined ECC for one h in order to 
reach stable plasma levels. Thereafter, blood and urine samples were collect­
ed at 20 to 40 m m intervals for the determination of PAH, inulin, creatini­
ne, sodium, and potassium levels. The mean values of two 20 to 40 min clea­
rance intervals were calculated before and during felodipine infusion. The 
renal clearance of inulin was taken as a measure of the glomerular filtration 
rate (GFR), that of PAH as the effective renal plasma flow (ERPF). The fil­
tration fraction (FF) was calculated as GFR/ERPF, and renal blood flow (RBF) 
was estimated using the formula: RBF = ERPF/(1-haematocrit). Renovascular re­
sistance (RVR) was defined as 1000 χ MAP/RBF (arbitrary units). Renal clea­
rances of sodium and potassium were expressed as a percentage of GFR: frac­
tional excretion (FE Na+, FE K +) 
Statistical comparisons for haemodynamic parameters were made with Student's 
t-test for paired observations. Changes in hormonal or renal function parame­
ters were evaluated with Wilcoxon's rank-sum test. A p-value below 0.05 was 
considered to be of statistical significance. Unless indicated otherwise, all 
values are given as means +_ SEM. 
The study protocol was approved by the Ethical Committee of the Sint Radboud 
Hospital, Nijmegen. All patients gave written informed consent. 
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RESULTS 
Haemodynamic effects. The haemodynamic effects of felodipine in all 16 hyper­
tensive patients are shown in Figure 1. At the end of the felodipine infusion 
systolic blood pressure had decreased with 15.0 ± 2.3%, diastolic blood pres­
sure with 17.θ ± 1.9%, and FVR with 66.9 ± 3.6%, compared with baseline va­
lues after one h supine rest. Heart rate had risen with IB.2 + 3.8%. 
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Figure 1: Haemodynamic effects of felodipine (0.01 mg/min intravenously du­
ring 120 m m ) in 16 patients with hypertension (means ± SEM) 
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Felodipine plasma levels rose during the infusion, to reach a peak between 90 
and 120 m m of infusion. Maximal plasma levels of felodipine (15.1 +.1.4 
nmol/1) coincided with maximal haemodynamic effects (Λ MAP = -20.1 + 2.2SÓ). 
When the felodipine infusion was discontinued, the haemodynamic parameters 
changed in the opposite direction, but had not returned to pretreatment 
values after 30 m m (p<0.01). Results in patients with impaired renal 
function did not differ from those in patients with a normal ECC. 
Hormonal effects. The hormonal effects of felodipine in the 10 previously un-
treated patients are shown in Figure 2. Felodipine caused an increase in 
PRA. The fall in plasma aldosterone just failed to reach statistical signifi-
cance. When all 16 patients were evaluated together, plasma aldosterone le-
vels were significantly lower after 80 (13.3 +_ 4.8 ng/100 ml) and 120 (12.6 _+ 
4.1 ng/100 ml) m m of infusion, compared to baseline (21.2 + 7.2 ng/100 ml, 
p<0.05 for both). During felodipine infusion there was a slight, but statis-
tically significant decrease in plasma potassium concentration from 3.63±0.16 
to 3.50+0.14 mmol/1, p<0.05). Plasma sodium concentration and Cortisol levels 
did not change. Plasma noradrenaline levels rose from 1.81 + 0.22 to 2.94 + 
0.31 nmol/1 at the end of the felodipine infusion (p<0.01) while plasma adre-
naline levels increased slightly from 0.14 + 0.03 to 0.18 + 0.03 nmol/1 
(p<0.01). 
Table II. Renal effects of intravenous felodipine in nine hypertensive 
patients3 
Before 
felodipine 
During 
felodipine 
Signifi-
cance*3 
Urine f low (ml /min) 
Ur inary Na+ e x c r e t i o n (μΕς/πιιη) 
U r i n a r y K+ e x c r e t i o n (μΕς/πιιη) 
ECC (ml/min/1.73m 2 ) 
GFR (ml/min/1.73m 2 ) 
ERPF (ml/min/1.73m 2 ) 
FF 
RBF (ml/min/1.73m2) 
RVR (U) 
FE Na + {%) 
FE K+ (S) 
6.4 ± 1.7 
124.6 ± 23.7 
20.0 ± 5.6 
67.7 ± 18.0 
47.2 ± 14.3 
239.9 ± 70.3 
0.22 + 0.02 
378.7 ± 113.6 
123 ± 54 
5.17 ± 1.79 
34.3 ± 13.6 
9.8 ± 2.6 
222.9 ± 39.1 
14.8 ± 5.0 
76.7 + 19.2 
50.2 ± 14.8 
295.4 ± 83.3 
0.20 ± 0.03 
463.1 + 133.7 
97 ± 43 
7.07 i 2.19 
24.1 ± 8.7 
P<0.01 
P<0.01 
U.S. 
N.S. 
N.S. 
P<0.05 
N.S. 
P<0.05 
P<0.05 
P<0.01 
N.S. 
a: Means ± SEM are g i v e n 
b: Wi lcoxon'e rank-sun t e s t . N.S.: not s i g n i f i c a n t 
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Renal effects. Felodipine caused an increase in urine flow, natnuresis and 
in fractional excretion of sodium (Table II). Urinary potassium excretion did 
not change. ERPF and RBF increased during felodipine infusion. Renovascular 
resistance decreased. Endogenous creatinine clearance and GFR did not change 
significantly. FF decreased in seven patients. 
PRA (ng/ml/h) 
U felodipine iv 
Aldosterone 
(ng/100ml) 
20-1 
Noradrenaline 
( n m o l / l ) 
Plasma felodipine 
(nmol/l ) 
20 η 
ν\λ 
•^нЛ 
^ ! 
^^-к. 
τ 1 1 1 1 — 
0 40 80 120 150 
Time ( mm) 
Figure 2: Effects of felodipine (0.01 mg/min intravenously during 120 min) on 
plasma renin activity (PRA), aldosterone, end catecholamine levels 
in 10 hypertensive patients who had not received any 
antihypertensive drugs in the previous 3 weeks (means ± SEM, 
* p<0.05, ** p<0.01: Wilcoxon's rank-sum test) 
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Side effects. Side effects of felodipine were mostly minor, and did not ne-
cessitate any specific therapeutic measures. Both headache and flushing oc-
curred in 6 patients. Two patients complained of a full bladder sensation and 
two experienced orthostatic dizziness after micturition. No other side ef-
fects were observed. 
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DISCUSSION 
The calcium antagonist felodipine, infused intravenously at a rate of 0.01 
mg/min during 120 m m in 16 patients with moderate renal or essential hyper-
tension, caused a decrease in blood pressure through vasodilation, as shown 
by increases in forearm blood flow, renal blood flow, and by side effects 
such as flushing, which may be an indication of an increase in blood flow to 
the skin. Other authors have also documented the generalized vasodilation 
caused by felodipine in more invasive study protocols in hypertensive pa-
tients (IB), and in experimental animals (5). The fall in blood pressure was 
maximal at the end of the felodipine infusion, when felodipine plasma levels 
were highest. After the infusion of felodipine was discontinued all haemody-
namic parameters measured returned in the opposite direction. Together with 
the stabilisation of haemodynamic parameters during one h of supine rest be-
fore the felodipine infusion started (see Figure 1), this shows that the 
changes in study parameters during the infusion were due to felodipine. Table 
III shows that the changes in blood pressure, FBF, and FVR in this study were 
Table III. Comparison of the effects of felodipine, 0.01 mg/min 
intravenously, in 10 normotensive subjects and in 10 untreated 
patients with hypertension3. 
S y s t o l i c b lood pressure 
D i a s t o l i c b lood pressure 
Heart r a t e 
Forearm blood f low 
Forearm vascular 
r es i s t ance 
Plasma r e n i n a c t i v i t y 1 3 
Plasma aldosterone13 
Plasma noradrenal ine1 3 
Plasma adrenal ine1 3 
Fe lod ip ine plasma l e v e l 
(nmol /1) 
Normotensive 
sub jec ts 
+1.2 
-2 .9 
+14.2 
+30.0 
-20.7 
+31.3 
-26 .1 
+71.7 
+50.5 
14.6 
+ 1.1 
+ 1.9 
+ 2.2 
+ 11.3 
+ 5.9 
+ 20.6 
+ 10.4 
+ 9.7 
+ 16.0 
+ 0.9 
Hypertensive 
sub jec ts 
-14.8 
-17 .6 
+17.7 
+39.4 
-61.5 
+46.4 
-21.1 
+68.9 
+29.1 
15.9 
+ 3.0 
+ 2.4 
+ 4.5 
+ 20.8 
+ 4.6 
+ 15.4 
+ 13.0 
+ 10.6 
+ 6.7 
+ 1.8 
S i g n i f i -
cance0 
P<0.01 
P<0.001 
N.S. 
P<0.001 
P<0.001 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
a: Percentual changes after 90 m m infusion, compared to baseline. Means ± 
SEM are given. 
": For hypertensive patients: changes after 120 min are given for hormonal 
parameters 
c: Student's t-test for unpaired observations. N.S.: not significant 
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similar in direction, but of a greater magnitude than those we found in 
another study in 10 healthy volunteers (mean age 32 years) where felodipine 
was infused at the same rate of 0.01 mg/min (Θ). Stronger haemodynamic ef­
fects in hypertensive than in normotensive subjects have also been described 
for nifedipine (9). The changes in heart rate, PRA, and plasma noradrenaline 
levels were not different in hypertensive and in normotensive subjects. This 
is an unexpected finding since the decrease in blood pressure was much larger 
in the hypertensive than in the normotensive subjects. It might be explained 
by an attenuation of the baroreceptor response to dihydropyndines in the hy­
pertensive patients (19,20,21). 
In our present study we found no difference in haemodynamic effects between 
hypertensive patients with norma] and those with impaired renal function. 
Useful properties of dihydropyndines in the chronic treatment of hyperten­
sion in patients with impaired renal function have been described by several 
authors (22,23). In a 24- to 48-week follow-up study of chronic treatment 
with felodipine in our clinic, hypertensive patients with renal failure had 
the same antihypertensive response as those with normal renal function (unpu­
blished observations). 
The fall in blood pressure caused by felodipine led to compensatory increases 
in heart rate, PRA, and plasma noradrenaline levels. Thus, in this respect 
felodipine does not behave differently from nifedipine (2), or from other pe­
ripheral vasodilators (7,24). If these findings are confirmed in a chronic 
trial of felodipine in hypertensive patients, combination therapy with a be-
ta-adrenoceptor blocking drug may be useful. Combination of a dihydropyndine 
calcium antagonist with a beta-blocker has been reported to be a safe and ve­
ry effective antihypertensive regimen (2). Although felodipine caused a rise 
in PRA, this was not followed by an increase in plasma aldosterone levels. As 
many patients in our study had renal failure, and some of them had undetec­
table aldosterone levels before felodipine was infused, a statistically sig­
nificant decrease in plasma aldosterone could only be detected when data from 
all 16 patients together were analysed. Felodipine may thus exert a negative 
influence on adrenal responsiveness to angiotensin II, as has been described 
for other calcium antagonists (25,26). 
Despite a lowering of blood pressure due to vasodilation, we observed an 
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acute diuretic and natriuretic effect of felodipine as we found in normoten-
sive individuals (8). The rise in fractional excretion of sodium suggests 
that an inhibitory effect of felodipine on tubular sodiun reabsorption may be 
responsible for this natnuresis. This inhibition may be a direct effect of 
the drug on the tubule, as suggested by DiBona and Sawin on the basis of 
their micropuncture studies in rats (27). The fall in plasma aldosterone le-
vels may also be responsible for a decrease in distal tubular sodiun reab-
sorption. The results of our study leave open the possibility that tubular 
sodimi reabsorption is altered secondarily to haemodynamic changes in the 
kidney caused by felodipine. As the ERPF rose more than the GFR (which did 
not change significantly, although in 7 out of 9 patients an increase was 
noted) a fall in FF was found in seven patients. Only in the two patients who 
had the lowest GFR before felodipine was infused (7 and 12 ml/min/1.73 m2) 
there was a rise in FF. A decrease in FF caused by felodipine was also noted 
by other authors (18) and may possibly be explained by a preferential effect 
of felodipine as an efferent renal vasodilator. An increase in ERPF relative 
to GFR leads to proportionally less removal of protein-free ultrafiltrate. 
This causes a rise in peritubular capillary hydrostatic pressure and a fall 
in peritubular oncotic pressure with consequent inhibition of proximal sodium 
reabsorption (28,29). 
In conclusion, the slow intravenous administration of the calcium antagonist 
felodipine caused the haemodynamic and hormonal effects that may be expected 
from an arteriolar vasodilator. Renal sodium excretion rose, which may be due 
to a change in intrarenal haemodynamics, probably in combination with direct 
tubular effects of the drug. 
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CHAPTER VIII 
EFFECTS OF DIHYDROPYRIDINE CALCIUM ANTAGONISTS ON RABBIT RENAL NA,K-ATPase 
ACTIVITY IN VITRO 
H.J. Kloke, H.G.P. Swarts, H.E. Sluiter*, F.Th.M. Huysmans*, 
and J.J.H.H.M. de Pont 
Departments of Biochemistry and Internal Medicine, Division of Nephrology*, 
University of Nijmegen, The Netherlands 
SUMMARY 
We studied the effects of the dihydropyndine calciim antagonists nimodipine, 
nitrendipine, msoldipine, mludipine, nifedipine, and felodipine (10"5 M) on 
purified Na,K-ATPase isolated from rabbit kidney outer medulla. No effect of 
the drugs on enzyme activity could be detected either in optimal or subopti-
mal substrate conditions. Na.K-ATPase activity, partly inhibited by the addi­
tion of ouabain (10-6M), Ca 2 + (Ю-'м), arachidonic acid (4.10-5M), or by a 
solution containing a Na-K-ATPase inhibitor isolated from porcine blood, also 
did not change when a dihydropyndine was added. Thus, in contrast to the 
stimulatory effect of dihydropyndines on Na,K-ATPase activity of vascular 
smooth muscle cells, there was no such effect on renal Na,K-ATPase. This is 
better in line with the known diuretic and natriuretic effects of these drugs 
in normotensive and in hypertensive man. 
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INTRODUCTION 
In arterial hypertension, in general a disorder of vascular smooth muscle 
tone leading to an increase in total peripheral resistance of the vascular 
bed, increased levels of cytosolic calciun have been described by several 
authors (1,2). Many vasodilatory drugs which lower blood pressure in hyper­
tension, may also interfere with calcium metabolism of the vascular smooth 
muscle cell (1). The so-called calcium antagonists are arterial vasodilators 
with clinically useful antihypertensive properties, especially the most po­
werful subclass of dihydropyndine derivatives (3,4). These drugs lower blood 
pressure in hypertensive patients at plasma concentrations in the nanomolar 
range (3,4). The exact cellular mechanism of action of dihydropyndines thus-
far remains unknown, but may involve more than just blocking calciun influx 
into the vascular smooth muscle cell through the calcium channels (5). Intra­
cellular mechanisms of action have also been postulated, such as an interfe­
rence with calmodulin mediated activation of myosin light chain kinase 
(6,7). Theoretically a stimulation of calcium efflux mechanisms might also 
play a role (S). According to Blaustein's hypothesis, an increase in Na,K-
ATPase activity in the cell membrane leads to a more effective Na,Ca exchange 
mechanism and thus Ca^+ extrusion from the cell (9). Pan and Jams (10) found 
that the dihydropyndines nimodipine and nitrendipine, but not nifedipine, 
stimulated the Na,K-ATPase system of vascular smooth muscle by 120 and 50% 
respectively. They postulated that the resulting more efficient calcium ex­
trusion from the vascular smooth muscle cell could be partly responsible for 
the powerful vasodilatory effects of the drugs. 
As the enzyme Na,K-ATPa3e is one of the most important effectors of renal tu­
bular sodium reabsorption (11,12,13), a similar stimulatory effect of dihy­
dropyndines on renal Na,K-ATPase, would tend to enhance sodi ил reabsorption 
by the kidney. This is obviously not in accordance with clinical practice, 
where sodium retention is only seen in a minority of hypertensive patients 
who are treated chronically with dihydropyndines (14,15). Many authors have 
even documented a natriuretic effect of these drugs in short term studies 
(16,17). This diuretic effect may not be solely dependent on a change in re­
nal hemodynamics secondary to vasodilation (18,19). 
Because of the discrepancy between the supposed alternative mechanism of ac-
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tion of dihydropyndines on vascular smooth muscle and their natriuretic po-
tency in clinical use, we tested the effects of several dihydropyndines, all 
with a documented vasodilatory and antihypertensive effect, on rabbit renal 
Na,K-ATPase in vitro. 
86 
MATERIALS AND METHODS 
Membrane-bound Na,K-ATPase was isolated and purified from rabbit renal outer 
medulla according to the method of Jergensen (20). In the final preparation 
Na,K-ATPase activity constituted over 955» of total ATPase activity. 
The dihydropyndines nimodipine (NIM), nitrendipine (NIT), nisoldipine (NIS), 
niludipine (NIL) and nifedipine (NIF) were dissolved in а 1л dimethylsulfoxi-
de solution (DMSO), yielding a final concentration of 10"bM of the drugs. A 
few experiments were also performed with the related drug felodipine (FEL), 
in the same concentration of 10" M. The solvent did not exert any influence 
on renal Na,K-ATPase activity. 
The dihydropyndine containing solutions were added to Na,K-ATPase containing 
membrane suspensions (final protein concentration: 3.2 μg/ml) that, apart 
from 10"bM dihydropyndine, were of the following chemical composition: 100 
mM NaCl, 10 mM KCl, 5 mM МдСІг, 30 тМ imidazole, 0.1 тМ EDTA and 5 тМ Νθ2ΑΤΡ 
at pH 7.4 for the determination of total ATPase activity, and the same 
without KCl and with the addition of 0.1 mM ouabain, for the determination of 
non-Na,K-dependent ATPase activity. Na,K-ATPase activity was calculated as 
the difference between total and non-Na,K-dependent ATPase activities (21). 
Assay tubes were prepared at ¿PC, and the reaction was started by the 
addition of the enzyme. 
After 20 to 60 minutes incubation time at ЗТ^С the ATP hydrolysis was stopped 
by the addition of trichloroacetic acid (4.3S), ammoniumheptamolybdate 
(0.575%) and ЕеЗОц (4.6л) to the reaction tubes. The amount of phosphate ge­
nerated by ATP hydrolysis was measured as phosphomolybdate by spectrophotome-
tnc analysis at 700 nm absorption after 30 minutes at IPC. Enzyme activity 
in the presence of a dihydropyndine was expressed as a percentage of the ac­
tivity in the presence of the respective solvent alone. 
As some dihydropyndines may be degraded by exposure to UV light, the experi­
ments took place in a darkened room which was lightened by a special lamp 
emitting only wavelengths above 500 nm. 
Since it may be difficult to measure a further stimulation of Na,K-ATPase by 
the dihydropyndines in the relatively optimal substrate conditions mentioned 
above, some experiments were repeated in the presence of suboptimal Na and К 
concentrations (18 mM NaCl and 0.8 mM KCl respectively), and when the enzyme 
was inhibited by the addition of 10"6M ouabain, 10~3M Ca 2 + or 4x10 M arachi-
domc acid in the reaction tubes. Finally a few experiments were performed 
with the addition of 10 μΐ of a solution containing a circulating pump inhi­
bitor, isolated from pig blood. 
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RESULTS 
Exposure of rabbit renal Na,K-ATPase to 10~^M concentrations of the dihydro-
pyndines tested, did not lead to a change in the activity of the enzyme, 
whether measured under optimal substrate (Na/K) conditions or not (Table I). 
There was no difference between individual effects of the various dihydropy-
ndines. Nimodipine and nitrendipine did not behave differently from the 
other drugs. 
Table I. Effects of dihydropyndmes on rabbit renal Na.K-ATPase activity in 
vitro in optimal and suboptimal substrate conditions 
Substrate conditions 
Optimal 
Na+dlO mM) 
K+ (10 mM) 
Suboptimal 
Na+(18 mM) 
K+ (10 mM) 
Suboptimal 
Na+(110 mM) 
K+ (0 .8 mM) 
Residual enzyme activity(Ä)a 
Number of experiments 
Enzyme activity in the presence 
of dihydropyndine (10"'M)'D 
100 7 1 + 9 31 ± 7 
NIM 
NIT 
NIS 
NIL 
NIF 
FEL (n=2) 
99 ± В 
102 ± 12 
101 + 8 
103 ± 8 
98 ± 4 
102 ± 4 
105 ± 15 
102 + 7 
106 ± 13 
1 0 4 + 1 0 
98 + 9 
97 ± 1 
103 + 5 
100 + 5 
99 ± 7 
102 ± 4 
99 + 4 
107 + 2 
compared to enzyme activity under control conditions in the presence of 
optimal substrate conditions (means ± SD) 
means ± SD, data expressed as a percentage of activity with solvent alone 
added to reaction mixture. 
(NIM:nimodipine, NIT:nitrendipine, NISrnisoldipine, NILrmludipine, 
NIFrmfedipine, FELifelodipine) 
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The results, shown in Table II, indicate that the 44 to 6750 reduced activity 
of the Na,K-ATPase, when incubated with partly inhibitory concentrations of 
ouabain, calcium ions, or arachidonic acid, was not increased by any of the 
dihydropyndines either. Finally, in three experiments we could not detect a 
change in the inhibition of the enzyme when a dihydropyndine was added to an 
otherwise optimal reaction mixture containing an inhibitor isolated from por­
cine blood (Table II). 
Table II: Effects of dihydropyndines on rabbit renal Na,K-ATPase activity in 
the presence of various inhibitors in otherwise optimal substrate 
conditions (Na=110 mM, K=10 mM) a 
Ouabain Ca^+ Arachidonic Porcine 
acid inhibitor 
(10-6M) (Ю-'М) (4X10-5M) 
Residual enzyme activity {%)B 5 6 + 4 3 4 + 2 3 3 + 1 3 57 ± 15 
Number of experiments 4 4 3 3 
Enzyme activity in the presence 
of dihydropyndine (ICT'M) 
NIM 
NIT 
NIS 
NIL 
NIF 
FEL (n=2) 
a
: compared to enzyme activity under control conditions in the presence of 
optimal substrate conditions (means + SD) 
°: means + SD, data expressed as a percentage of activity with solvent alone 
added to reaction mixture. For abbrevations of various dihydropyndines: 
see Table I. 
101 ± 5 
98 + 6 
99 ± 7 
100 ± 10 
97 ± 8 
100 + 6 
102 ± 11 
105 + 12 
109 + 9 
97 ± 12 
103 ± 8 
107 ± 13 
92 + 7 
8 8 + 8 
97 + 2 
9 3 + 9 
99 ± 5 
-
104 + 6 
102 ± 9 
97 ± 13 
99 + 7 
98 ± 4 
-
89 
DISCUSSION 
We found no effect of the dihydropyndines tested on the intrinsic activity 
of rabbit renal membrane Na,K-ATPase. None of the dihydropyndines caused a 
change in Na,K-ATPase activity when the enzyme was previously inhibited by 
suboptimal Na + and K + concentrations. This indicates that the affinity for 
these cations was not diminished by the drugs. The same may be concluded with 
regard to the affinity for the inhibitors that were used. Taken together, it 
is unlikely that dihydropyndines have an important effect on Na,K-ATPase. 
Pan and Jams (10) described a stimulating effect of nimodipine and nitrendi­
pine on vascular smooth muscle Na,K-ATPase in rats.According to Blaustem's 
hypothesis (9) they thus provided evidence for an alternative explanation of 
the vasodilatory properties of the drugs. However, should renal Na,K-ATPase 
react in the same way to dihydropyndines, this would lead to renal sodium 
and fluid retention. This is relatively seldom seen in clinical practice when 
these drugs are given to hypertensive patients (14,15). 
Our in vitro results showing a lack of stimulation by dihydropyndines of re­
nal Na,K-ATPase, are thus more in keeping with the clinical situation in man, 
but appear to be at variance with the stimulation by dihydropyndines of the 
enzyme in rat vascular smooth muscle reported by Pan and Jams (10). The as­
say conditions and the concentrations of the dihydropyndines we used, were 
comparable to those used in their experiments. One possible explanation is 
the existence of species differences in Na,K-ATPase characteristics. Alterna­
tively, renal Na,K-ATPase may behave differently from vascular smooth muscle 
Na,K-ATPase. To test this latter possibility more directly, we tried to iso­
late and purify vascular smooth muscle Na,K-ATPase from rabbit aorta and por­
tal vein and from rat aorta microsomal fractions. Although we employed the 
Pan and Jams technique (10), preliminary experiments failed to show consis­
tent results, due to a very low relative Na,K-ATPase yield (5%, or maximally 
155o after pretreatment with Nal (22)). However, it should be realized that 
Pan and Jams also calculated Na,K-ATPase activity from the difference be­
tween separately determined total and non-Na,K dependent ATPase activities, 
and that the absolute increase in Ма,К-АТРазе activity formed only a small 
fraction of total ATPase activity (less than 10% for 10"^M nimodipine). Fur­
thermore, it may be considered unlikely that the reported difference in beha-
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viour with respect to Na,K-ATPase of two closely related drugs such as ni­
trendipine and nifedipine (10), that have almost identical haemodynamic and 
diuretic effects in man (16,23), is of any clinical relevance. 
In conclusion, we did not find a major stimulating effect of various dihydro-
pyndines (Ю'-'М) on renal Na,K-ATPase in vitro. The presence of such an ef­
fect would have made it difficult to explain the natriuresis observed when 
these drugs are taken by normotensive and hypertensive man. Due to difficul­
ties in the purification of vascular smooth muscle Na,K-ATPase we have not 
been able to confirm or refute Pan and Jams' data showing a stimulation of 
vascular Na,K-ATPase by some dihydropyndines in the rat. The discrepancy be­
tween Pan and Jams' results and ours, can possibly be explained by interspe­
cies differences or, alternatively, by a difference in behaviour between re­
nal tissue and vascular smooth muscle Na,K-ATPase. 
ACKNOWLEDGEMENTS 
This study was supported in part by a grant (С Θ1.2Θ6) from the Dutch Kidney 
Foundation. Bayer AG (Leverkusen, Germany) and AB Hässle (Mölndal, Sweden) 
kindly supplied the dihydropyndines tested. The circulating inhibitor iso-
lated from pig blood was generously provided by J. Timmermans, Dept.Bioche-
mistry, University of Nijmegen. 
91 
REFERENCES 
1. Erne, P., P. Bolli, E. Bürgisser, and F.R. Bühler. 1984. Correlation of 
platelet calcium with blood pressure. Effect of antihypertensive thera-
py. N.Engl.J.Med. 310: 1084-1088. 
2. Bruschi, G., M.E. Bruschi, M. Caroppo, G. Orlandini, M. Spaggiari, and 
A. Cavatorta. 1985. Cytoplasmic free (Ca^ -··) is increased in the platelets 
of spontaneously hypertensive rats and essential hypertensive patients. 
Clin.Sci. 68: 179-184. 
3. Lederballe Pedersen, 0. 1981. Calcium blockade as a therapeutic principle 
in arterial hypertension. Acta Pharmacol.Toxicol. 49 (Suppl.II): 1-31. 
4. Sluiter, H.E., F.Th.M. Huysmans, Th.A. Thien, and R.A.P. Koene. 1985. 
Haemodynamic effects of intravenous felodipine in normotensive and hyper-
tensive subjects. Drugs 29 (Suppl.2): 144-153. 
5. Jams, R.A., and A. Scnabine. 1983. Sites of action of Ca^ ··· channel in-
hibitors. Biochem.Pharmacol. 32: 3499-3507. 
6. Bostròm, S-L., B. Ljung, S. Mardh, S. Forsén, and E. Thulin. 1981. Inter-
action of the antihypertensive drug felodipine with calmodulin. Nature 
292: 777-778. 
7. Daly, M.J., S. Perry, W.G. Nayler. 1983. Calcium antagonists and calmodu-
lin: effect of verapamil, nifedipine and diltiazem. Eur.J.Pharmacol. 90: 
103-108. 
8. Gray, H.H., L. Poston, V.E. Johnson, and P.J. Hilton. 1985. Effect of the 
calcium antagonist verapamil on human leucocyte sodiun transport in vi-
tro. Clin.Sci. 68: 239-241. 
9. Blaustein, M.P. 1977. Sodium ions, calcium ions, blood pressure regula-
tion, and hypertension: a reassessment and a hypothesis. Am.J.Physiol. 
232: C165-C173. 
10. Pan, M., and R.A. Jams. 1984. Stimulation of Na+, K+-ATPase of isolated 
smooth muscle membranes by the Ca2+ channel inhibitors, nimodipine and 
nitrendipine. Biochem.Pharmacol. 33: 787-791. 
11. Epstein, F.H., and P. Silva. 1974. Role of sodium, potassium-ATPase in 
renal function. Ann.N.Y.Acad.Sci. 242: 519-526. 
12. Katz, A.I. 1982. Renal Na-K-ATPase: its role in tubular sodium and potas-
sium transport. Am.J.Physiol. 242 : F207-F219. 
13. Cruz-Soto, M., J.E. Benabe, J.M. López-Novoa, and M. Martinez-Maldonado. 
1984. Na+-K+-ATPase inhibitors and renin release: relationship to cal-
cium. Am.J.Physiol. 247: F650-F655. 
14. Olivan, M.Т., С. Bartorelli, A. Polese, С. Fiorentini, P. Moruzzi, and 
M.D. Guazzi. 1979. Treatment of hypertension with nifedipine, a calcium 
antagonistic agent. Circulation 59: 1056-1062. 
15. Collste, P., M. Damelsson, D. Elmfeldt, E. Feleke, A. Gelin, T. Hedner, 
and L. Rydén. 1985. Long term experience of felodipine in combination 
with ß-blockade and diuretics in refractory hypertension. Drugs 29 
(Suppl.2): 124-130. 
16. Ene, M.D., P.J. Williamson, C.J.C. Roberts, and G. Waddell. 1985. The na-
tnuresis following oral administration of the calcium antagonists - ni-
fedipine and nitrendipine. Br.J.Clin.Pharmacol. 19: 423-427. 
17. Sluiter, H.E., F.Th.M. Huysmans, Th.A. Thien, H.J.J. van Lier, and 
R.A.P. Koene. 1985. Haemodynamic, hormonal and diuretic effects of felo-
dipine in healthy normotensive volunteers. Drugs 29 (Suppl.2): 26-35. 
18. Dietz, J.R., J.O. Davis, R.H. Freeman, D. Villarreal, and S.F. Echten-
kamp. 1983. Effects of intrarenal infusion of calcium entry blockers in 
anesthesized dogs. Hypertension 5: 482-488. 
19. DiBona, G.F., and L.L. Sawin. 1984. Renal tubular site of action of felo-
dipine. J.Pharmacol.Exp.Ther. 228: 420-424. 
92 
20. Jergensen, P.L. 1974. P u r i f i c a t i o n and c h a r a c t e r i z a t i o n o f (Na++K+)-ATP-
ase. I I I . P u r i f i c a t i o n from the o u t e r medul la o f mammalian kidney a f t e r 
s e l e c t i v e removal o f membrane components by sodium d o d e c y l s u l p h a t e . B i o -
c h i m . B i o p h y s . A c t a . 356: 36-52. 
2 1 . Schuurmans Stekhoven, F., and S.L. B o n t i n g . 1981. Transport adenosine 
t r i p h o s p h a t a s e s : p r o p e r t i e s and f u n c t i o n s . Phys io l .Rev. 6 1 : 1-76. 
22. Nakao, T., Y. Tashima, К. Nagano, and M. Nakao. 1965. H igh ly s p e c i f i c so-
d ium-potass ium-act ivated adenosine t r i p h o s p h a t a s e from v a r i o u s t i s s u e s o f 
r a b b i t . Biochem.Biophys.Res.Commun. 19: 755-758. 
23. Rutsch, W., and H. Schmutzler. 1984. Comparison o f the acute hemodynamic 
e f f e c t s o f n i f e d i p i n e w i t h n i t r e n d i p i n e and a study o f the e l e c t r o p h y s i o ­
l o g i c a l e f f e c t s o f n i t r e n d i p i n e i n man. J.Cardiovasc.Pharmacol. 6 
( S u p p l . 7 ) : S1011-S1015. 
93 

CHAPTER IX 
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University of Nijmegen, The Netherlands 
SUMMARY 
Changes in systemic and renal haemodynamics and in the renin-angiotensin sys-
tem caused by infusion of the calcium antagonist felodipine were investigated 
in a placebo-controlled study in 12 normotensive volunteers before and during 
a graded infusion of angiotensin II (All). In spite of a fall in blood pres-
sure through vasodilation, felodipine had a natriuretic effect. There was on-
ly a transient rise in effective renal plasma flow (ERPF), whereas glomerular 
filtration rate (GFR) did not change. Urinary sodium excretion remained ele-
vated when ERPF had normalized. Urinary potassium excretion did not change. 
All-induced reductions in ERPF, GFR, and sodium excretion were abolished by 
felodipine. Felodipine also partly antagonized the rise in plasma aldosterone 
levels caused by All. We conclude that the natriuretic effect of dihydropyn-
dine calcium antagonists is probably not caused by a single mechanism, but 
may be dependent on changes in renal haemodynamics together with a diminished 
sodium reabsorption at multiple tubular sites. Interference with angiotensin 
II-mediated renal mechanisms, and an impairment of the action of aldosterone 
may contribute to the effects observed. 
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INTRODUCTION 
Felodipine is a dihydropyndine derivative with powerful antihypertensive ef-
fects in patients with primary and secondary forms of hypertension (1,2). 
Like other dihydropyndines, felodipine has a natriuretic effect (3), which 
may attenuate the compensatory renal sodium retention that is observed with 
other vasodilators during chronic antihypertensive therapy (4,5). 
In an earlier study in 10 normotensive volunteers, this natriuretic effect of 
felodipine was clearly shown (6). Urinary potassium excretion did not rise, 
which is in agreement with a distal tubular site of action of dihydropyndi-
nes (7,8). Clearance studies in man indicate that dihydropyndines may also 
influence proximal tubular sodium reabsorption (8,9). 
Theoretically, changes in renal haemodynamics and interference with the re-
nin-angiotensin-aldosterone system could play a role in the observed natriu-
retic effect of felodipine. Such an interference is plausible, since many of 
the physiological effects of All are dependent on the availability of intra-
cellular free calcium ions (10), and are antagonized when a calcium antago-
nist is given. In several experimental settings in vivo and in vitro, calcium 
antagonists interfered with the effects of All on blood pressure (11,12,13), 
renal blood flow (14,15,16), renal sodium excretion (17), and aldosterone re-
lease (12,18). 
In the present study in 12 healthy volunteers, we investigated the effects of 
a slow intravenous infusion of felodipine on renal haemodynamics and on na-
tnuresis. Increasing doses of All were infused, together with felodipine or 
placebo, in order to test the hypothesis that a blockade of the renal effects 
of All plays a role in the natnuresis caused by calcium antagonists. 
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METHODS 
Twelve healthy male volunteers, aged 22-30 years (mean 24 years) participated 
in the study. Pretreatment supine blood pressure (124/74+2/2 mmHg, mean t 
SEM, Erkameter 300), body weight (73.7+2.0 kg) and height (180.9±1.4 cm) were 
within normal limits. The subjects followed a moderately sodium-restricted 
(100 mmol Na+/24 h) diet for one week before each experimental day. Two 24 h 
urine collections were analyzed for sodium, potassium, calciun, and creatini-
ne. The study subjects had not drunk alcoholic beverages, or smoked, for at 
least 24 h before each experiment. No coffee or tea was allowed in the last 
12 h before the experiments. Felodipine or placebo were infused with an in-
terval of three weeks in a double-blind, randomized way. 
After a light breakfast at 7 a.m., the volunteers came to the ward, where the 
experiments took place between 8.30 a.m. and 16.30 p.m. No food or drink was 
given while the infusions lasted. After one h of supine rest, felodipine was 
infused during 300 m m , starting with a dose of 0.009 mg/min, which was de-
creased to Tb% after 40 m m to prevent a further increase in plasma levels 
of felodipine. On placebo days, felodipine solvent was used. A graded infu-
sion of the All-analogue val ^ -angiotensin Il-asp^ß-amide (Hypertensin^, 
Ciba) was given from 140 min after the start of the felodipine infusion on-
wards. Each dose (0.3, 1.0, and 3.0 ng/kg/min) was infused during 40 m m . 
From 60 m m before the infusion of felodipine, until the end of the study, 
supine blood pressure was measured with an automatic recorder ( Artenosonde 
1225). Heart rate was calculated from a simultaneously recorded 25 mm/min 
ECG-stnp. Forearm blood flow (FBF) was measured with mercury strain gauge 
plethysmography, while the circulation of the hand was excluded by a pulse 
cuff. 
Renal clearances were measured under conditions of moderate water diuresis. 
An oral water load of 625 ml was taken with breakfast, and urinary fluid and 
sodium losses were replaced by the intravenous infusion of a NaCl 0.25% in 
glucose 3.3% solution at a rate of 400 ml per h from 80 m m before the felo-
dipine infusion until the end of the experiments. The amount of NaCl infused 
equalled the estimated losses in urine during placebo infusion and losses 
caused by the sampling of blood (6). Inulin (laevofructosan, Inutest"), and 
para-aminohippurate (PAH) were infused in an isotonic solution containing 10% 
mulin and 2.5% PAH in distilled water. After a priming dose of this solution 
(0.4 ml/kg, infused during 10 m m , immediately before the start of the 
felodipine infusion) a maintenance infusion was started at a rate of 0.004 
times the pre-estimated endogenous creatinine clearance (ECC, ml/min). After 
one h of equilibration, blood and urine samples for the determination of 
inulin, PAH, creatinine, sodium, potassium, and chloride levels were taken at 
the beginning and at the end of each clearance period of 40 min. Urine 
samples were collected by spontaneous voiding in the upright position. Two 
clearances were determined during felodipine infusion before All, one during 
each dose of All, and a final one after the discontinuation of the All 
infusion. 
Blood samples for the determination of felodipine plasma levels (19) were ta-
ken at 40 m m intervals. Blood samples for the determination of plasma renin 
activity (PRA,20), aldosterone, and Cortisol levels (21), were taken before 
felodipine infusion, before All infusion, and at the end of the infusion of 
each dose of All. Plasma levels of adrenaline, noradrenaline (22), ionized 
calcium, corrected for pH (ICA 1 , Radiometer, Copenhagen), phosphate, magne-
sium, uric acid and osmolality, as well as haemoglobin and haematocnt were 
measured before felodipine, before All, and at the end of the infusion of 
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Α Π . In the urine samples collected at the same times, osmolality, calcium, 
phosphate, urate, and magnesium levels were determined. Body weight was mea­
sured before and at the end of each experiment. 
The mean values of five consecutive 2 m m interval readings of blood pressure 
and heart rate were used for analysis. FBF was calculated from the mean of 
five curves. Mean arterial pressure (MAP) was calculated as diastolic blood 
pressure plus one third of the pulse pressure. Forearm vascular resistance 
(FVR) was calculated as MAP/FBF, and expressed in arbitrary units. The renal 
clearance of inulin was taken as a measure of glomerular filtration rate 
(GFR), that of PAH as the effective renal plasma flow (ERPF). Assuming a 
nearly constant renal extraction of PAH, renal blood flow (RBF) is approxi­
mated by the formula RBF=ERPF/(1-haematocrit), and renovascular resistance 
(RVR, arbitrary units) by 1000xMAP/RBF. Filtration fraction (FF) was defined 
as GFR/ERPF, and expressed as a percentage. Free water clearance (C H2O) was 
calculated as urinary flow (V) minus osmolal clearance (C osm). The fractio­
nal excretion rate (FE) of a substance was defined as the renal clearance of 
that substance divided by the GFR χ 100ÍK. 
Statistical comparisons between paired observations were made with Student's 
t-test if a normal distribution applied, or with Wilcoxon's rank-sum test. 
Comparisons between curves were made with a distribution-free analysis of va-
riance (23). A p-level of 0.05 or less was considered to be of statistical 
significance. All values given in text, tables and figures are expressed as 
means ± SEM. 
The study protocol was approved by the Ethical Committee of the Sint Radboud 
Hospital, Nijmegen. All subjects gave written informed consent. 
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RESULTS 
EfTect of felodipine infusion on haemodynamics, hormonal, and biochemical pa­
rameters. Except for plasma aldosterone levels (7.0±0.5 ng/100 ml on felodi­
pine days (F), and 10.2±1.1 ng/100 ml on placebo days (P), p<0.05), all base­
line values were similar on both study days, including 24 h urinary sodium 
excretion (95±12 mmol (F) vs 111+17 mmol (Ρ)). During the initial period of 
140 m m , felodipine caused a decrease in systolic (-5.3+1.5SÍ) and diastolic 
(-7.4+3.7Й) blood pressure (Fig.1) and in MAP (-6.6+2.3%). Heart rate (+13.7 
+2.7%) and FBF (+38.7+10.1%) rose, and FVR decreased by 28.4±6.0%. During 140 
min infusion of placebo, none of these parameters showed significant changes. 
Systolic blood pressure 
(mmHg ) 
120 -, 
Diastolic blood pressure • 
(mmHg ) 
- ι 80 -
Heart rate 
(beats/mm 
75 
65 
Forearm vascular resistance 
( U ) 
-l 75-1 I-
55 -
0 40 80 120 
Time (mm) 
Figure 1. Haemodynamic effects of intravenous felodipine (·) or placebo (o) 
in 12 healthy normotensive volunteers (mean + SEM; *:p<0.05, 
**:p<0.01, ***:p<0.001). Pretreatment value (t=0 m m ) : mean of 10 
Artenosonde readings and/or FBF curves after 60 m m of supine 
rest. 
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Figure 2 shows the changes in hormonal parameters during felodipine and pla­
cebo infusion. PRA and plasma aldosterone levels did not change significantly 
during felodipine, but fell on placebo (PRA: p<0.01, aldosterone: p<0.001). 
Plasma noradrenaline levels rose significantly on felodipine (p<0.001), and 
did not change on placebo. Plasma adrenaline and Cortisol levels remained un­
changed. Felodipine did not affect plasma levels of sodium, potassium, chlo­
ride, creatinine, ionized calcium, phosphate, magnesium, and uric acid. 
Plasmarenin Plasma Plasma 
activity aldosterone noradrenaline 
(ng/ml/h) (ng/100ml) (nmol/1) 
ι 1 -' ι 1 ι 1 
0 U0 0 uo о uo 
Time (mm) 
Figure 2. Hormonal changes caused by felodipine (·) or placebo (o) infusion 
in 12 healthy normotensive volunteers (mean ± SEM). Significance of 
changes compared with placebo *:p<0.05, **:p<0.01, ***:p<0.001). 
Renal effects of felodipine. After 100 min infusion of felodipine there were 
rises in urine flow, ECC, ERPF, RBF, and urinary sodium and chloride excre­
tion (Table I). GFR and FF were not significantly different (p<0.10) on felo­
dipine and placebo days. RVR was lower on felodipine. 
After 140 min infusion of felodipine (Table I) the differences between felo­
dipine and placebo in ECC, ERPF, RBF, and RVR had disappeared, but urine flow 
remained slightly higher on felodipine. The marked increases in absolute and 
fractional urinary sodium and chloride excretion persisted. Felodipine had no 
influence on urinary potassium excretion, nor did it change calcium, phospha­
te, magnesium, urate, and free water clearances. 
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Table I . Effects of felodipine or placebo infusion on renal function1 
Duration of Infusion 
100 mm 140 min 
Urine fi 
ECC 
ERPF 
GFR 
FF 
RBF 
RVR 
UNaV 
uciv 
UKV 
FE Na + 
ow (mi/min) 
(mi/min) 
(mi/min) 
(mi/min) 
(») 
(mi/min) 
(U) 
(μΓηοΙ/πιιη) 
(цтоі/тіп) 
(цтоі/тіп) 
(Я) 
a: (means ± SEM), * 
Fi 
р<0 
Blodipine 
10.4±0.6* 
167+9** 
775+54* 
119 + 5 
15.9+0.9 
1307+80* 
61±4*** 
408+40*** 
329140*** 
61+19 
2.52+0.29*** 
.05, ** р<0.01, 
Placebo 
8.2±0.5 
144±8 
651+46 
111±5 
17.3±0.5 
1090±76 
78±5 
135±16 
105±15 
38±14 
0.89±0.12 
*** р<0.001, 
Felodipine 
8.1+0.6* 
136±8 
617+40 
99+4 
16.4±0.7 
1054+57 
75+6 
396+34*** 
327140*** 
50+12 
2.94±0.30*** 
compared with 
Placebo 
6.5+0.3 
138+6 
615+29 
109+5 
17.8+0.5 
1023±46 
81+4 
137+19 
101+16 
45+13 
0.91+0.13 
placebo 
Effects of felodipine on angiotensin II induced haemodynamic, hormonal, and 
renal changes. All infusion led to dose-related increases in systolic and 
diastolic blood pressures on placebo (Fig.3). The rise in diastolic blood 
pressure on 0.3 and 1.0 ng/kg/min All was not significant on felodipine. The 
fall in heart rate seen on the highest dose of All during placebo was not ob­
served on felodipine. All caused only minor changes in FBF and FVR. 
The All-induced fall in PRA was not blocked by felodipine, but the dose-re­
lated rise in plasma aldosterone levels was partly antagonized (Fig.4). Plas­
ma levels of potassium were not altered by All. A small decrement in plasma 
Cortisol levels on both higher doses of All was not observed when felodipine 
was infused concomitantly. There were only minor changes in plasma adrenaline 
and noradrenaline levels during All infusion on both study days. 
All the changes in renal haemodynamics caused by All were antagonized by fe­
lodipine (Fig.5) All-induced falls of ERPF and RBF were not seen when felo­
dipine was also infused, and felodipine abolished the dose-related increase 
in RVR. While All caused a decrease in ECC and GFR during placebo infusion, 
these parameters increased when All was given during felodipine. The rise in 
FF during All was similar on both study days. Forty minutes after the end of 
the All infusion, all the renal haemodynamic parameters had returned to pre-
AII levels (Fig.5). Graded doses of All caused statistically significant and 
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ûsystolic blood pressure 
(mmHg) 
angiotensin II 
.8 
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Δ diastolic blood pressure 
( mmHg) 
• 12 
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КО 180 220 260 300 
Time (mm) 
Figure 3. Effects of graded doses (in ng/kg/min i.v.) angiotensin II on blood 
pressure and heart rate during infusion of felodipine (·) or 
placebo (o) in 12 healthy volunteers (means ± SEM; *:p<0.051 
**:p<0.01, felodipine compared with placebo). 
progressive falls in urinary flow rate, and in absolute and fractional excre­
tion of sodium and chloride (Fig.6). These changes were not seen when felodi­
pine was concomitantly infused. During felodipine infusion, urinary sodium 
and chloride excretion even rose on the highest All dose. Urinary potassium 
excretion remained unchanged at both occasions. On the highest dose of All, 
С H2O fell from 2.8 + 0.4 ml/mm to 0.4 + 0.3 ml/min on placebo (p<0.01), but 
only from 3.1 + 0.6 to 1.5 + 0.7 ml/min on felodipine (NS). 
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Figure 4. Effects of graded doses (in ng/kg/min i.v.) angiotensin II on PRA 
and plasma aldosterone levels during infusion of felodipine (·) or 
placebo (o) in 12 healthy volunteers (means ± SEM; *:p<0.05, felo­
dipine compared with placebo). 
Plasma levels of felodipine and side effects. After 40 min infusion, felodi­
pine plasma levels were 7.1 ± 0.5 nmol/1. Thereafter, mean plasma levels rose 
by about 1 nmol/1 per hour. At the end of the All administration felodipine 
plasma levels were 11.6 ± 0.4 nmol/1. 
Side effects of felodipine reported by the study subjects were mostly minor, 
and did not necessitate the interruption of felodipine infusion (Table II). 
Headache and flushing were more frequently seen with felodipine than with 
placebo. Body weight decreased from 73.9±2.0 kg to 73.4+2.0 kg on felodipine, 
while it increased from 73.5±1.9 kg to 73.8±1.9 kg on placebo (p<0.01). The 
amounts of fluid infused did not differ (3776+92 m] on felodipine, 3739±162 
ml on placebo). 
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Figure 5. Effects of graded doses (in ng/kg/min i.v.) angiotensin II on renal 
haemodynamics and glomerular filtration during infusion of felodi-
pine (·) or placebo (o) in 12 healthy volunteers (means ± SEM, 
*:p<0.05, **:p<0.01, **»:p<0.001, felodipine compared with place-
bo). 
Table II. Side effects of felodipine infusion in 12 healthy 
volunteers» 
Headache 
Flushing 
Warm feeling 
Palpitations 
Orthostatic dizziness 
F e l o d i p i 
10** 
10** 
5 
1 
3 
ne Placebo 
2 
2 
2 
1 
1 
<·: ** p<0.01, compared with placebo, X^-test 
105 
Aurine flow(ml/nmn) -
angiotensin li 
AUNa V(umol/min ) 
260 300 
Time (min) 
Figure 6. Effects of graded doses ( i n ng/kg/min ι .v .) angiotensin I I on u r i ­
nary flow r a t e , renal excretion of sodium (UNaV) and fract ional 
excretion of sodium (FE Na"·") during infusion of felodipine ( · ) or 
placebo (o) in 12 healthy volunteers (means ± SEM, *:p<0.05, 
** :p<0.01, ***:p<0.001, felodipine compared with placebo) 
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DISCUSSION 
The intravenous infusion of the calcium antagonist felodipine in 12 healthy 
volunteers caused a fall in blood pressure and forearm vascular resistance, 
and an increase in heart rate and plasma noradrenaline levels. This is in ac-
cordance with the concept that felodipine acts as an arteriolar vasodilator 
(24). PRA and aldosterone levels were unchanged on felodipine, but fell on 
placebo. As in our previous study (6), felodipine had a natriuretic effect in 
spite of the fall in blood pressure through vasodilation. 
Several factors may be involved in the increase in renal sodium excretion 
caused by dihydropyndines. They may cause an increase in GFR and thereby in 
filtered load of sodium (25,26,27). Secondly, an increase in ERPF in the ab-
sence of a change in GFR resulting in a decreased FF was described for felo-
dipine in hypertensive patients by Andersson et al (28). This could diminish 
proximal tubular sodium reabsorption by causing a decrease in peritubular on-
cotic pressure and a rise in peritubular hydrostatic pressure (29,30). Third-
ly, a decrease in proximal tubular sodium reabsorption in the absence of a 
change in renal haemodynamics was reported for the dihydropyndines nitrendi-
pine and nicardipine in clearance studies in normotensive volunteers during 
maximal water diuresis (8,9). Another possibility is that dihydropyndines 
lead to a diminished distal tubular sodium reabsorption, as was reported in 
rats (7), and in man (8). Since the renm-angiotensin-aldosterone system in-
terferes with sodium reabsorption by all the mechanisms mentioned above, an 
antagonism of this system by dihydropyndines may contribute to their natriu-
retic effect (17). 
We did not find a significant change in GFR on felodipine. This means that an 
increase in filtered load of sodium cannot explain the natriuretic effect of 
the drug. We observed a transient rise in ERPF, which may have contributed to 
the initial rise in FE Na+ by a decrease in FF. However, FE Na+ remained ele-
vated when ERPF had returned to placebo values. This implies that felodipine 
infusion may also lead to a decrease in tubular sodiun reabsorption, indepen-
dent of a change in renal haemodynamics. Obviously, this reasoning holds only 
true if we assume that felodipine does not interfere with renal extraction of 
PAH, or in other words, that PAH clearance accurately reflects ERPF also du-
ring felodipine infusion. As our study was performed under conditions of only 
moderate water diuresis, a direct interference of felodipine with proximal 
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tubular sodium reabsorption can neither be excluded nor demonstrated. In ac-
cordance with the literature (7,31,32), we did not find an increase in urina-
ry potassium excretion in spite of the rise in FE Na+. Thus, felodipine may 
interfere with potassiun excretion at the level of the distal tubule, or lead 
to diminished sodium reabsorption beyond the Na+/K+ exchange site. 
The influence of an antagonism of the renin-angiotensm-aldosterone system on 
the natriuretic effect of felodipine was investigated by the graded infusion 
of angiotensin II. Schoback et al (33) have provided evidence that the plasma 
levels caused by these doses of intravenous All may be of clinical rele-
vance. We acknowledge however, that locally generated endogenous All may have 
different physiological effects in the kidney (34). Felodipine antagonized 
renal sodium retention caused by exogenous All. Several other renal effects 
of All were also blocked by the drug. Thus, All-mediated renal vasoconstric-
tion was counteracted, and felodipine caused relative increases in ERPF and 
GFR. The increase in GFR in the presence of an unchanged ERPF that was seen 
when All was infused together with felodipine is not readily explained, but 
suggests that afferent vasoconstriction by All is more sensitive to calcium 
antagonism than efferent vasoconstriction (25). During the highest dose of 
All the rise of blood pressure was not antagonized by felodipine. In the pre-
sence of afferent vasodilation this may have led to an increased intraglome-
rular pressure causing the rise in GFR. However, such an explanation does not 
hold for the rise in GFR seen on both lower doses of AIT during felodipine, 
unless it is assumed that also at these doses the pressure in the afferent 
arterioles was raised, while this was not reflected in a measurable rise of 
systemic blood pressure. Felodipine may also increase GFR during All infusion 
through inhibition of All-mediated contraction of the glomerular mesangium, 
which is calcium dependent and can be blocked by the calcium antagonist vera-
pamil in the rat (16). This might help to prevent the fall in GFR during All, 
but it cannot explain the rise in GFR that was actually seen. 
During placebo, All caused a fall in sodium excretion. Although this fall may 
relate to the decrease in GFR, the fall in the fractional excretion of sodium 
clearly shows that All causes a rise in tubular sodium reabsorption. Three 
different mechanisms may contribute to this rise. Firstly, renal haemodynamic 
changes leading to an increase in FF favour proximal tubular sodi un reabsorp-
tion (29,30). Secondly, All directly stimulates proximal tubular sodium reab-
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sorption (35,36). Finally, All increases plasma aldosterone levels. Since the 
effects of aldosterone on the cortical collecting tubule take some time to 
develop (37), it is unlikely that aldosterone effects play a role in the an-
tinatnuresis seen during the first two doses of A H in the present study. 
Felodipine antagonized the All-induced fall in FE Na"1". The observed rise in 
FF during felodipine infusion makes a change in renal haemodynamics a less 
likely cause of this antagonism. Therefore, felodipine must interfere with 
the direct effects of All on the proximal tubule. The increase in FE Na+ du-
ring the highest dose of All and felodipine was not accompanied by a rise in 
potassium excretion. Felodipine only partly blocked All-induced rises in 
plasma aldosterone levels. Taken together, this is compatible with an inter-
action of felodipine with aldosterone effects on the cortical collecting tu-
bule. 
In conclusion, felodipine had a natriuretic effect in spite of a fall in 
blood pressure through vasodilation. Urinary potassium excretion remained un-
changed. The natriuresis caused by felodipine was accompanied by a transient 
rise in ERPF, but persisted when ERPF had normalized. Felodipine antagonized 
the decrease in FE Na+ caused by infusion of angiotensin II. The drug also 
abolished the fall in ERPF caused by All, and turned the All-mediated fall in 
GFR into a rise. Furthermore, felodipine partly antagonized the rises in 
plasma aldosterone levels caused by All. Our results indicate that the na-
triuretic effect of felodipine is caused by several mechanisms. A change in 
renal haemodynamics may play a role, but tubular effects, independent of such 
a change, are probably as important. All these changes may partly be related 
to an antagonism by felodipine of All-mediated sodium retention. 
Further studies are reguired in sodium depleted human volunteers and experi-
mental animals to investigate the possible role of an antagonism of endoge-
nous All in the natriuretic effects of felodipine. Besides, since the effects 
of calcium antagonists and All may differ between normotensive and hyperten-
sive subjects (8,38), studies of a possible antagonism of All-mediated renal 
effects by felodipine in hypertensive patients are warranted. 
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CHAPTER Χ 
GENERAL DISCUSSION 

GENERAL DISCUSSION 
Dihydropyndine calcium antagonists (DHP) are arteriolar vasodilators which 
have been successfully applied in the chronic treatment of arterial hyperten­
sion. They are also effective in hypertensive patients with renal insuffi­
ciency. The dihydropyndine nifedipine safely lowers blood pressure in pa­
tients with a hypertensive crisis (1). Although clinical experience with the 
use of DHP in antihypertensive treatment only comprises the last decade -
their clinical use in hypertensive patients was still considered to be expe­
rimental in 19Θ1 (2) - some authors already advocate them as first-line anti­
hypertensive drugs. Based on findings of a greater effect in the treatment of 
older patients, and in hypertensive patients with a low plasma renin activi­
ty, Bühler (3) suggested that DHP monotherapy may replace treatment with diu-
retics in the near future. Hypertensive patients often need lifelong medical 
treatment in order to prevent long-term complications of their disease. This 
means that antihypertensive drugs must be safe, and free of disturbing side 
effects to the patient. Many of the side effects of arteriolar vasodilators 
are caused by the compensatory reactions of the body that antagonize their 
antihypertensive action (4). The investigation of the compensatory mechanisms 
elicited by the DHP vasodilators is thus highly relevant to the determination 
of their clinical usefulness as monotherapy in the chronic treatment of hy-
pertension. 
In the following, the results of the investigations with the dihydropyndines 
nifedipine and felodipine as presented in this thesis will be discussed under 
four headings: 
- antihypertensive effects of felodipine in patients with a hypertensive 
emergency and in the chronic treatment of hypertension 
- antihypertensive effects of dihydropyndines and sympathetic counterregula-
tion 
- effects of dihydropyndines on the renin-angiotensin system 
- effects of dihydropyndines on renal function and sodi ил reabsorption 
Antihypertensive effects of felodipine 
The intravenous infusion of felodipine in patients with a hypertensive emer­
gency proved to be safe and very effective. All patients, including those in 
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whom nifedipine had been ineffective, responded with a satisfactory fall in 
blood pressure during the infusion. Intravenous felodipine was well tolerat-
ed, and led to disappearance of the symptoms of hypertensive crisis. The re-
lationship between felodipine plasma levels and the fall in blood pressure 
makes it possible to titrate the antihypertensive effect by adjustment of the 
infusion rate. On empirical grounds we advocate a total initial dose of 0.02 
mg/kg felodipine and a starting infusion rate of 0.01 mg/min. 
Oral felodipine led to a fall in blood pressure of 2b% during long term 
treatment in patients with moderate to severe hypertension. Unresponsiveness 
did not occur, while patients with renal failure needed the same dose of fe-
lodipine as those with normal renal function. There was a correlation between 
mean individual log plasma levels of felodipine and its antihypertensive ef-
fect. No patient had to withdraw because of side effects of the drug. The de-
sign of the study did not allow us to investigate the effects of age and pre-
treatment PRA on the antihypertensive effect of felodipine. Felodipine had no 
adverse effect on renal function. In order to achieve a stable reduction in 
blood pressure, felodipine had to be given three to four times daily. This is 
leas often than is necessary for nifedipine capsules, but too frequent to 
make the present tablet formulation of felodipine the ideal drug to use in 
long-term antihypertensive treatment. In our study, chronic felodipine thera-
py was combined with a beta-adrenoceptor blocking drug because of reflex car-
diostimulation in most patients. By contrast, a diuretic to combat oedema 
formation was needed in only 40S of patients, which is substantially less 
than was needed in patients with similar clinical characteristics treated 
with minoxidil (5), a vasodilator of the same potency as felodipine (6). Pa-
tients with an endogenous creatinine clearance above 70 ml/min/1.73m2 even 
needed a diuretic in only 25% of cases. This diuretic "sparing" effect of fe-
lodipine in chronic antihypertensive treatment was also reported by others 
(7), and may be related to the natriuretic effects of the drug. Thus, felodi-
pine is a useful drug for the medical treatment of moderate to severe hyper-
tension. Felodipine monotherapy is not possible in this category of patients 
as concomitant treatment with a beta-blocker will almost always be indicat-
ed. Further studies of the effect of felodipine monotherapy in less severe 
hypertension are indicated to establish its place in first-line antihyperten-
sive therapy. 
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Long-term felodipine treatment led to a rise in plasma levels of ionized cal­
cium and phosphate. These changes were independent of the fall in blood pres­
sure, of the use of diuretics, or of a change in renal function. This sug­
gests that calcium antagonists may interfere with calcium and phosphate meta­
bolism, possibly at the level of intestinal reabsorption. In view of the con­
troversies that exist in the literature (Θ) regarding the relation between 
calcium metabolism and hypertension, it seems necessary to study the effects 
of felodipine on calcium metabolism in more detail. Resnick et al (9) sug­
gested that a relation between hormonal changes (vitamin D, PTH, calcitonin) 
which influence plasma calcium levels, and the antihypertensive effects of 
calcium antagonists may exist. 
The antihypertensive effect of dihydropyndines and sympathetic counterrequ-
lation 
Although we did not study this aspect of DHP therapy in much detail , it is 
clear from the rise in heart rate and plasma noradrenaline levels in the 
acute studies, and from the need for concomitant beta-blocker treatment du­
ring long-term felodipine therapy, that the sympathetic nervous system is ac­
tivated by the DHP. This activation may counteract the antihypertensive ef­
fect of nifedipine and felodipine by a rise in cardiac output, activation of 
the renin-angiotensin system, and activation of postsynaptic alpha-receptors, 
which causes vasoconstriction. In Chapter II we demonstrated that the postsy­
naptic alpha-1-blocker prazosin indeed enhanced the antihypertensive effect 
of nifedipine, suggesting that reflex sympathetic stimulation effectively an­
tagonizes the vasodilatory effects of DHP through alpha-1-receptor activa­
tion. From our study it is not clear whether the postsynaptic alpha-2-гесер-
tors also play a role in this regard. These receptors have been demonstrated 
to exist in man, and to contribute to vascular tone (10,11). The normaliza­
tion of blood pressure by nifedipine after pretreatment with prazosin indi­
cates that either alpha-Z-receptor stimulation plays no role in the sympathe­
tic counterregulation of vasodilation, or that calcium antagonism interferes 
with alpha-2-mediated vasoconstriction, as was demonstrated in experimental 
animals by van Meel et al (12). The antihypertensive efficacy of nifedipine 
in a patient with a phaeochromocytoma, who had high levels of circulating ca­
techolamines indicates that this latter possibility is the most likely one. 
119 
Further studies on the role of vascular alpha-2-receptors in the regulation 
of blood pressure, and on the influence of calciun antagonists on the recep-
tor-mediated effects in man are needed. 
Effects of dihydropyndines on the renin-angiotensin system 
Activation of the renin-angiotensin system counteracts the antihypertensive 
effects of vasodilators (4) by causing renal retention of sodium and water 
(angiotensin II, aldosterone), and also by causing peripheral vasoconstric-
tion, directly or via a potentiation of the effects of noradrenaline on vas-
cular smooth muscle (angiotensin II). Our acute studies with nifedipine and 
felodipine indicate that DHP stimulate plasma renin activity, but do not 
cause a rise in plasma aldosterone levels. This can be explained by a partial 
antagonism of angiotensin II effects on aldosterone release, as shown m 
chapter IX. It is doubtful whether this lack of aldosterone response contri-
butes to the acute natnuresis of DHP as some time is needed for aldosterone 
to exert its effects on the cortical collecting tubule. 
Effects of dihydropyndines on renal function and sodium reabsorption 
DHP have a slight diuretic effect, that could be relevant for chronic antihy-
pertensive treatment, and explain why a diuretic is often not needed in spite 
of a fall in blood pressure through vasodilation. Hypertensive patients show-
ed a similar diuretic response as normotensive volunteers. Our acute studies 
in healthy subjects show that the natriuretic effect of felodipine is at 
least partly caused by a change in tubular reabsorption of sodium. This ef-
fect is probably not due to an inhibition of renal Na,K-ATPase. A fall in 
proximal tubular sodium reabsorption secondary to a transient change in renal 
haemodynamics, or as a direct effect of felodipine on the tubular cell, might 
be involved. We found evidence for a distal tubular effect of felodipine, in-
dependent of changes in plasma aldosterone levels. The antagonism by felodi-
pine of the renal effects of exogenous angiotensin II suggests that DHP may 
interfere with the sodiun-retaining properties of the intrarenal renin-angio-
tensin system. We have preliminary evidence that the acute natriuretic effect 
of felodipine persists during chronic therapy with the drug. Haemodynamical-
ly-mediated changes in proximal tubular reabsorption of sodium are almost 
certainly involved in this natriuretic effect on chronic treatment, as we 
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found a consistent rise in ERPF, accompanying the increase in fractional ex-
cretion of sodium, while GFR did not change. 
Further studies of the natriuretic effect of felodipine in normotensive and 
in hypertensive subjects are warranted. The role of an inhibition of the in-
trarenal renin-angiotensin system in the natriuretic effect of felodipine can 
be better appreciated when this sytem is manipulated by varying the sodium 
content in the diet or by pretreatment with a converting enzyme inhibitor. 
Finally, calcium antagonists inhibit the haemodynamic effects of noradrenali-
ne in the isolated rat kidney (13). Noradrenaline, like angiotensin II, in-
duces renal sodium retention (14). Therefore, studies on the effects of cal-
cium antagonists on noradrenal ine-induced renal sodimi retention are also 
needed. 
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SAMENVATTING 
Calciumantagonisten zijn perifere vaatverwijders die de laatste jaren met 
succes zijn toegepast bij de behandeling van hypertensie. Het werkingsmecha-
nisme van deze heterogene groep geneesmiddelen is nog niet geheel opgehel-
derd. Met name in de dihydropyridine subgroep, waartoe nifedipine en felodi-
pine behoren, komt het antihypertensief effect primair tot stand door een 
verlaging van de perifere weerstand. Een negatief effect op het hart in de 
zin van een vertraging van de pnkkelgeleiding of een daling van het hartmi-
nuutvolume wordt bij hypertensiebehandeling met dihydropyndines zelden waar-
genomen. Op het niveau van de gladde spiercel van de vaatwand blijken Cal-
ciumantagonisten de passieve instroom van calciunionen vanuit de extracellu-
laire vloeistof naar het cytoplasma van de cel te verminderen. Het betreft 
hier een blokkade van de zogenaamde calciumkanalen die geopend worden wanneer 
de cel wordt blootgesteld aan prikkels als rek en membraandepolansatie, maar 
ook van kanalen die opengaan na interactie van vasoactieve hormonen als nor-
adrenaline en angiotensine II met hun receptoren in de membraan van de gladde 
spiercel. Aldus voorkomen Calciumantagonisten een stijging van de intracellu-
laire concentratie van geïoniseerd calcium die noodzakelijk is voor contrac-
tie van de gladde spiercel. Meer omstreden zijn remmende effecten van calcium 
antagonisten op het vrijkomen van calciumionen uit intracellulaire organellen 
(met name gestimuleerd door noradrenaline en angiotensine II) en een stimule-
rende invloed op het calciumtransport vanuit de cel naar de extracellulaire 
vloeistof. 
Verlaging van de bloeddruk door vaatverwijding leidt via prikkeling van de 
baroreceptoren tot een compensatoire sympathicusstimulatie met als gevolg 
verhoging van hart frequentie en hartminuutvolume, vasoconstnctie en renine 
productie, en via stimulatie van het renine-angiotensme-aldosteron systeem 
(RAAS) en renale hypoperfusie tot water-en zoutretentie. Deze compensatieme-
chanismen kunnen het antihypertensief effect van artenolaire vaatverwijding 
antagoneren, en kunnen leiden tot bijwerkingen als palpitaties en de vorming 
van oedeem. Hierom wordt chronische antihypertensieve therapie met vaatver-
wijders als hydralazine, diazoxide en minoxidil meestal gegeven in combinatie 
met beta-blokkers en diuretica. Er zijn aanwijzingen dat deze compensatoire 
reacties in mindere mate worden gezien bij hypertensiebehandeling met calcium 
antagonisten, hetgeen deze middelen theoretisch geschikt maakt voor toepas-
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sing als monotherapie. Doelstelling van het onderzoek was inzicht te verkrij-
gen in de effectiviteit van de dihydropyndine calcium antagonist felodipine 
in de acute en chronische behandeling van hypertensie, alsmede in de mate 
waarin het antihypertensieve effect van dihydropyndines reacties uitlokt in 
de vorm van sympathicusactivatie, stimulatie van het RAAS, en natnumretentie 
door de nier. 
Felodipine bleek, langzaam intraveneus toegediend, de ernstig verhoogde 
bloeddruk bij patiënten met een hypertensieve crise effectief en veilig te 
verlagen. Het middel werd door de patiënten goed verdragen, de mate van da-
ling en de bloeddruk kon redelijk nauwkeurig worden getitreerd door de 
infusiesnelheid aan te passen, en na bestrijding van de acute periode kon de 
behandeling zonder problemen worden overgenomen met felodipine per os. Felo-
dipine bleek ook effectief in de chronische behandeling van patiënten met een 
refractaire, matig ernstige hypertensie. Hypertensiebehandeling met felodipi-
ne, meestal gecombineerd met een beta-blokker, leidde bij deze patiënten tot 
een daling van de bloeddruk met 25% in een 24 tot 48 weken durende vervolg-
studie. Er was geen verschil in effect tussen patiënten met een normale en 
een gestoorde nierfunctie. De daling van de bloeddruk leidde met tot een 
achteruitgang in de nierfunctie. Terwijl in veel gevallen een beta-blokker 
nodig was om palpitaties of een te snelle hartfrequentie te verminderen, had 
slechts een minderheid van de patiënten een diureticum nodig om oedeemvorming 
secundair aan de hypertensiebehandeling met vaatverwijding te voorkomen. Toe-
voegen van beta-blokker of diureticum leidde wel tot verdwijnen van palpita-
ties en tot verminderen van oedeem, maar had geen noemenswaardig effect op de 
bloeddruk. Felodipine werd goed verdragen, maar moest in de meeste gevallen 
drie tot vier keer per dag worden gedoseerd in verband met een vrij korte 
werkingsduur. 
Bij de acute toediening van nifedipine en felodipine trad een stijging op van 
het plasma noradrenalinegehalte, een uiting van compensatoire sympathicus-
pnkkeling. Hierbij passen ook stijgingen van hartfrequentie en plasma renine 
activiteit (PRA). De waargenomen versterking van het acute antihypertensieve 
effect van nifedipine door voorbehandeling met de postsynaptische alpha-1 
blokker prazosine wijst erop dat door sympathicuspnkkeling vrijkomend nor-
adrenaline inderdaad het antihypertensieve effect van dihydropyndines kan 
tegengaan. Nifedipine voorkwam ook de stijging van de bloeddruk die optrad 
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tijdens de mictie bij een patiente met een phaeochromocytoom van de blaas. 
Het is mogelijk dat dit samenhangt met een interactie van dihydropyndines 
met de effecten van prikkeling van postsynaptische alpha-2 receptoren, die 
vasoconstnctie veroorzaken en kunnen worden geactiveerd door circulerend 
noradrenaline, dat bij deze patiente in hoge concentratie voorkwam en nog 
verder steeg tijdens de mictie. 
Activering van het RAAS zou het bloeddrukverlagende effect van dihydropyndi-
nes kunnen verminderen door water- en zoutretentie in de nier te stimuleren 
(aldosteron, angiotensine II), en door de vasoconstnctoire effecten van an-
giotensine II. In de acute studies met nifedipine en met felodipine trad wel 
een stijging op van de PRA, maar niet van het aldosteron.Dit zou kunnen be-
rusten op een gedeeltelijke blokkade van de effecten van angiotensine II op 
de secretie van aldosteron. Omdat het enige tijd duurt voordat een aldoste-
ronstijging leidt tot natriumretentie door de nier, is het echter onwaar-
schijnlijk dat een verminderde aldosteronreactie bijdraagt aan het, verderop 
te bespreken, acute diuretische effect van dihydropyndines. Het bloeddruk-
verhogende effect van lage doseringen exogeen angiotensine II werd slechts in 
geringe mate geantagoneerd door felodipine. 
Dihydropyndines hebben een gering diuretisch en natriuretisch effect, wat er 
mogelijk toe bijdraagt dat een diureticum maar betrekkelijk weinig frequent 
nodig is bij de chronische behandeling van hypertensie met deze middelen. Zo-
wel bij hypertensieve patiënten als bij normotensieve proefpersonen kon een 
acuut diuretisch en natriuretisch effect van felodipine worden aangetoond. 
Omdat de fractionele excretie van natnun ook steeg moet een gedeelte van dit 
natriuretisch effect worden toegeschreven aan een vermindering van de tubu-
laire natnumreabsorptie. Daarom werd het effect van dihydropyndines op het 
enzym Na,K-ATPase onderzocht, maar in een membraansuspensie afkomstig van 
nierweefsel in vitro kon geen invloed op dit enzym worden aangetoond. Het 
lijkt waarschijnlijk dat veranderingen in renale hemodynamiek direkt of indi-
rekt een rol spelen bij het natriuretisch effect van felodipine, hoewel een 
direkt effect van felodipine op de mertubuli zelf niet kan worden uitgeslo-
ten. Tenslotte zou toediening van dihydropyndines tot een toename om de re-
nale natriunexcretie kunnen leiden door te interfereren met de intrarenale 
effecten van het RAAS, aangezien felodipine niet alleen de natriumretentie 
door exogeen angiotensine II blokkeerde, maar pok de door angiotensine II ge-
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induceerde dalingen in GFR en ERPF en stijging in de niervaatweerstand voor-
kwam. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 6 maart 1954 te Groningen. 
Aan het Praedinius Gymnasium aldaar werd in 1972 het einddiploma gymnasium-ß 
behaald. Hij studeerde geneeskunde aan de Rijks Universiteit te Groningen, 
en behaalde in 1977 het doctoraalexamen, en in februari 1979 het artsexamen. 
Na enige maanden als waarnemend huisarts werkzaam te zijn geweest te 
Groningen werd de militaire dienstplicht vervuld te Apeldoorn in het oplei-
dingsinstituut der Koninklijke Marechaussee. Vanaf juli 1980 is hij in oplei-
ding tot internist in de Kliniek voor Inwendige Ziekten van het Sint Radboud-
ziekenhuis te Nijmegen (opleider: Prof.dr. A. van 't Laar). Deze opleiding 
werd in 1982 en 1983 voor anderhalf jaar onderbroken voor het verrichten van 
een deel van de in dit proefschrift beschreven studies. Hij is getrouwd met 
Truke Edens, en zij hebben een zoon: Hendrik Jan. 
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STELLINGEN 
I 
Langzame intraveneuze toediening van de dihydropyridine Calciumantagonist fe-
lodipine is een effectieve en veilige behandeling van een hypertensieve 
crise. 
(Dit Proefschrift) 
II 
De negatief inotrope en chronotrope effecten op het hart in vitro van de Cal-
ciumantagonist felodipine spelen bij de behandeling van hypertensiepati'énten 
een geringe rol, zodat het middel ook chronisch veilig kan worden gecombi-
neerd met een beta-blokker. 
(Dit proefechrift) 
III 
Bij patiënten met nierinsufficiëntie en hypertensie is bij chronische behan-
deling met de Calciumantagonist felodipine de mate van bloeddrukdaling van 
dezelfde grootte-orde als die verkregen met diazoxide of minoxidil. Gezien de 
geringe bijwerkingen en het natriuretisch effect van felodipine, verdient ge-
bruik van dit middel wellicht de voorkeur bij deze categorie patiënten. 
(Dit Proefschrift) 
IV 
Het natriuretisch effect van dihydropyridines wordt tenminste voor een deel 
veroorzaakt door hemodynamische veranderingen in de nier. Hierbij spelen ver-
anderingen in de activiteit van het intrarenale renine-angiotensine systeem 
een rol. 
(Dit Proefschrift) 
V 
Het is niet waarschijnlijk dat het natriuretisch effect van Calciumantagonis-
ten wordt veroorzaakt door toegenomen secretie van atriopeptine. 
VI 
Ondanks het acute uricosurische effect van dihydropyridines voorkomen deze 
middelen een jichtaanval niet. 
(Eigen vsarnoiing) 
VII 
Calciumantagonisten kunnen de nier mogelijk beschermen tegen beschadiging 
door toxische of ischaemische invloeden. Het klinisch belang hiervan dient 
nader te worden onderzocht. 
Vili 
Omdat bij niertransplantatiepatiënten de bloeddruk ook na enkele jaren nog 
spontaan kan dalen dienen therapeutische interventies als embolisatie van de 
eigen nieren ter bestrijding van hypertensie met grote terughoudendheid te 
worden toegepast. 
(Huysmans FThM, ноіішва AJ, Wetzele JFH, Koene RAP. Blood pressure changes after embolisation of hoet 
kidney in renal transplant patients. Lancet 1985; i: 344) 
IX 
Bij patiënten met SLE zonder klinische tekenen van een nieraandoening zoals 
proteinuric, gestoorde nierfunctie of afwijkingen in het urinesediment, be-
hoeft geen nierbiopsie te worden verricht. 
(Sluiter HE, Kallenberg CGH, van son Hjf Weening JJ, van der Heulen Jf The TH, van der Hem GK. When to 
perform a renal biopsy in syatonlc lupus erythematosus (SLE)? Neth.J.Mad. 1981; 24: 217-23) 
X 
Het hemolytisch uremisch syndroom kan recidiveren in een getransplanteerde 
nier. Het is niet uitgesloten dat cyclosporine deze recidiefkans vergroot, 
mogelijk via remming van prostacycline activiteit. 
(Sluiter HE, Meyer S. Een patiënte met ano&ie, hemorrhagische diathese en anurie. Ned.T.Geneesk. 1980; 
\24: 883-9. Leithner C, Sinzinger H, Pohanfca E, Schwarz H, Kretschmer G, Syre G. Recurrence of haemo-
lytic uraemic syndrma triggered by cyclosporin A after renal transplantation. Lancet 1982; i: 1470) 
XI 
De initi'éle toename van proteinuric bij patiënten met een membraneuze glome-
rulonefritis tijdens een kuur met hoge doses Prednison wijst niet op een 
schadelijke invloed van dit middel. 
(wetzele JFM, Gerlag PGG, Sluiter HE, Hoitsma AJ, Koene RAP. prednisone induced fluctuations of pro-
teinuria in patients vith a nephrotic syndrome. Nephron 1986, in press) 
XII 
Alhoewel de toename van de één seconde capaciteit (ESC) na bronchusverwijding 
ten opzichte van de uitgangswaarde van direkte therapeutische betekenis is 
voor de emfyseempatiënt, is het quotiënt van deze toename en van het verschil 
tussen uitgangs- en normaalwaarde van de ESC van grotere betekenis voor de 
uiteindelijke prognose van de patient. 
(postma DS, 1984, proefschrift Groningen) 
XIII 
Een gebrek aan zonlicht speelt mogelijk mede een rol bij de Pathogenese van 
de collumfractuur van de bejaarde patiënt. Wellicht ligt hier een nieuwe in-
dicatie voor het gebruik van de zonnebank. 
XIV 
Het, om budgettaire redenen, centraal regelen van temperatuur en luchtverver-
sing in werkkamers in overheidsgebouwen verstoort het werkklimaat. 
Nijmegen, 13 juni 19 6 Henk Sluiter 


